Thalassemia - The Inherited Blood Disorder

Iron Overload in Thalassemia: Why It Happens & How It's Monitored

2026-08-04T20:51:50.548+05:30

If you or your child live with thalassemia and receive regular blood transfusions, you've likely heard your care team mention "iron overload" or "iron levels" almost as often as they mention hemoglobin. It can feel like just when you've adjusted to managing one part of thalassemia, there's another layer to understand. This article explains why iron builds up in the first place, why it matters, and how it's tracked — so the monitoring your care team does makes more sense as part of the bigger picture.

For background on the transfusions that make iron monitoring necessary, see our companion guide on [blood transfusions for thalassemia, LINK PENDING].

Why Iron Overload Happens in Thalassemia

Iron overload in thalassemia comes from two directions, and understanding both helps explain why it affects even patients who might assume they're not "at risk" for too much iron.

The Transfusion Connection

Every unit of transfused blood contains iron, since iron is a core component of hemoglobin in donor red blood cells. The human body has no natural, active mechanism to excrete excess iron — it can regulate how much iron it absorbs from food, but once iron is in the body, there's no built-in "release valve." For patients receiving regular transfusions over months and years, this iron steadily accumulates in tissues.

Increased Iron Absorption From the Gut

Separately, thalassemia itself can cause the body to absorb more iron from food than it normally would, even in patients who aren't yet on a regular transfusion schedule. This happens because of how ineffective red blood cell production affects the body's iron-regulation signals. This is one reason iron-rich supplements and, in some cases, iron-fortified foods are generally avoided in thalassemia unless specifically directed by a physician — a topic we cover in more depth in our upcoming diet and nutrition article.

Why Excess Iron Is a Problem

Iron that isn't being used for healthy red blood cell production doesn't simply sit inertly in the body. Over years, it deposits in organs that aren't built to store it, including:

The heart — where iron accumulation is linked to heart rhythm problems and, if unmonitored long-term, heart failure
The liver — where it can contribute to liver damage or fibrosis over time
Endocrine organs — including the pancreas, thyroid, and pituitary gland, where iron buildup can affect hormone production, growth, and puberty in children and adolescents

This is why iron overload isn't just a side note to thalassemia treatment — it's one of the primary long-term health risks that ongoing monitoring and management aim to prevent.

How Iron Levels Are Monitored

Because iron overload develops gradually and doesn't always cause obvious symptoms early on, regular monitoring is essential rather than optional.

Ferritin Blood Tests

Serum ferritin is a blood test that reflects the body's iron stores and is typically checked at regular intervals (often every few months, though your care team will set the right frequency for you). Ferritin is a useful trend indicator over time, though it can also be affected by inflammation or illness, so your hematologist interprets it alongside other information rather than as a standalone number.

MRI (T2* Scans) for Organ-Specific Iron

Blood ferritin alone doesn't tell the whole story of how much iron has accumulated in specific organs like the heart and liver. A specialized MRI technique known as T2* (pronounced "T2 star") imaging is used to directly estimate iron levels in these organs. This is typically done periodically — often annually for many patients, though the right interval depends on individual risk and prior results — and is considered a key tool for catching organ-level iron buildup before it becomes symptomatic.

Signs That May Indicate Iron Overload

Because early iron overload often has no noticeable symptoms, most detection happens through the scheduled monitoring described above rather than through symptoms alone. That said, as iron accumulation becomes more significant over time, some patients may notice fatigue beyond their usual baseline, joint discomfort, changes in skin tone, or symptoms related to affected organs (such as irregular heartbeat). None of these signs are specific to iron overload on their own, so they should always be discussed with your care team rather than self-diagnosed.

How Iron Overload Is Managed

When monitoring shows iron levels rising, the standard approach is chelation therapy — medications that help the body bind and remove excess iron. Because chelation involves specific drugs, dosing, and monitoring protocols that must be individualized by a hematologist, we cover this in detail in a dedicated article: [Chelation Therapy Explained: Managing Iron Overload, LINK PENDING]. This article intentionally does not go into chelation drug specifics, since that decision belongs with your treating physician.

Why Regular Monitoring Matters

The core message worth taking away is this: iron overload is manageable when caught and tracked consistently, and much less manageable when it isn't. Because it tends to progress silently, showing up for the ferritin tests and T2* MRIs your care team recommends — even when you feel fine — is one of the most protective things a thalassemia patient or caregiver can do.

Frequently Asked Questions

Why does thalassemia cause iron overload? Two reasons: regular blood transfusions introduce iron directly into the body, and thalassemia itself can increase how much iron the gut absorbs from food. The body has no natural way to remove excess iron, so it accumulates over time.

How is iron overload measured in thalassemia patients? Primarily through serum ferritin blood tests, which track iron stores over time, and T2* MRI scans, which directly measure iron levels in specific organs like the heart and liver.

What organs are affected by iron overload? The heart, liver, and endocrine organs (including the pancreas, thyroid, and pituitary gland) are most commonly affected by long-term iron accumulation in thalassemia.

Can iron overload be reversed? Chelation therapy can help the body remove excess iron over time and is generally more effective the earlier it's started and the more consistently it's followed. Your hematologist can explain what's realistic for your specific case.

Do all thalassemia patients need to worry about iron overload? Patients who receive regular transfusions are at the highest risk, but even non-transfused patients with thalassemia can absorb more iron than typical due to the condition itself, so monitoring is usually recommended across thalassemia types with your care team's guidance.

Medical Disclaimer

This article is for general educational purposes only and does not constitute medical advice. Iron monitoring schedules, interpretation of ferritin or MRI results, and any decisions about chelation therapy should always be made with your hematologist based on your individual case. If you have concerns about symptoms possibly related to iron overload, contact your care team.

Sources

National Heart, Lung, and Blood Institute (NHLBI) — Thalassemia and iron overload information
Thalassemia International Federation — Guidelines for the Clinical Management of Transfusion Dependent Thalassaemia
Cooley's Anemia Foundation — Patient education on iron overload and monitoring
StatPearls (NCBI Bookshelf) — Thalassemia pathophysiology reference

Reviewer Flags (pending hematologist sign-off)

Ferritin testing frequency ("often every few months") — verify general accuracy without stating specific numeric protocols
T2* MRI frequency ("often annually") — confirm this is a reasonable general statement across patient risk profiles
Description of organs affected by iron overload — confirm completeness and accuracy (heart, liver, endocrine organs)
General statement on gut iron absorption mechanism — verify simplified explanation doesn't oversimplify to the point of inaccuracy
Confirm no implied dosing/drug-specific chelation content has leaked into this article (should stay deferred to dedicated chelation post)

Blood Transfusions for Thalassemia: How Often & What to Expect

2026-08-03T21:22:33.344+05:30

For many people living with thalassemia major, blood transfusions aren't an occasional medical event — they're a recurring part of life, scheduled almost like an appointment you build your month around. If you're newly diagnosed, or you're a parent trying to understand what's ahead for your child, the idea of regular transfusions can feel overwhelming at first. This guide walks through why transfusions are needed, how often they typically happen, and what actually happens during a visit — so you know what to expect rather than facing it blind.

If you haven't already, it may help to first read our overview of [thalassemia types and severity, LINK PENDING] to understand where your or your child's diagnosis fits, since transfusion needs vary significantly between thalassemia minor, intermedia, and major.

Why Blood Transfusions Are Central to Thalassemia Care

Thalassemia affects the body's ability to produce healthy hemoglobin, the protein in red blood cells that carries oxygen. In moderate-to-severe forms, the bone marrow can't keep up — red blood cells are fragile, short-lived, and too few in number. This leads to chronic anemia that, left untreated, causes fatigue, poor growth in children, bone deformities, and strain on the heart and other organs.

Regular blood transfusions replace those missing healthy red blood cells directly, giving the body enough oxygen-carrying capacity to function and grow normally. For people with thalassemia major, transfusions are considered the cornerstone of standard care, alongside monitoring for the iron buildup that transfusions can cause over time (more on that below).

How Often Are Transfusions Needed?

Transfusion frequency depends heavily on which type of thalassemia a person has and how severe it is.

Thalassemia major typically requires transfusions every two to five weeks, continued for life or until a curative treatment (such as bone marrow transplant) is pursued. The exact interval is individualized by a hematologist based on hemoglobin levels, growth, symptoms, and how quickly the body uses up transfused red cells.

Thalassemia intermedia is more variable. Some people need transfusions only occasionally — during illness, growth spurts, pregnancy, or surgery — while others eventually require a more regular schedule as they age.

Thalassemia minor (trait) generally does not require transfusions at all, since the anemia, if present, is usually mild.

Because these intervals vary so much person to person, this article can only describe general patterns. Your hematologist will set an individualized transfusion schedule based on your specific blood counts and clinical picture — this is not something to self-manage or estimate from general information online.

What Happens During a Transfusion Visit

For many families, the practical logistics of a transfusion day matter as much as the medical reasoning. Here's a general walkthrough of what a typical visit looks like, though specifics vary by hospital or clinic.

Pre-Transfusion Testing

Before blood is given, a sample is drawn to check current hemoglobin levels and to cross-match the donor blood for compatibility. This step is essential for safety and is a standard part of every visit — it's normal to have blood drawn twice on transfusion day (once for testing, once for the IV line used during the transfusion itself, though sometimes the same line is used for both).

During the Infusion

Blood is given slowly through an IV line, and vital signs (temperature, blood pressure, heart rate) are usually monitored periodically throughout. Most transfusions are uneventful, though clinical staff watch for early signs of a reaction, such as fever, chills, itching, or back pain, and can stop or slow the infusion if needed.

Typical Duration and Recovery

A single transfusion visit — including preparation, the infusion itself, and post-transfusion observation — commonly takes a few hours. Many patients say they feel noticeably more energetic in the days following a transfusion, as hemoglobin levels rise, and gradually more tired again as the transfusion interval approaches its end. This "cycle" of energy is something many long-term patients learn to plan their lives around.

Possible Side Effects and Reactions

Transfusions are generally safe, especially with modern blood screening and cross-matching, but as with any medical procedure, reactions can occur. These may include mild allergic responses (itching, rash), fever, or, less commonly, more significant immune reactions. Any symptoms during or after a transfusion — chills, difficulty breathing, unusual pain — should be reported to clinical staff immediately if they occur during the infusion, or to your care team promptly if they occur afterward.

This article does not cover management of transfusion reactions, as that is a clinical matter for your treating team, not something to self-diagnose or manage based on general information.

The Trade-Off: Transfusions and Iron Overload

Regular transfusions solve one problem — insufficient healthy red blood cells — but introduce another: each unit of transfused blood contains iron, and the body has no natural way to remove excess iron. Over years of regular transfusions, iron accumulates in the liver, heart, and endocrine organs, which is why iron monitoring and management become just as important as the transfusions themselves.

We cover this in detail in our companion article on [iron overload in thalassemia, LINK PENDING], including how it's monitored and what long-term management looks like.

Questions to Ask Your Care Team

Every patient's situation is different, and a conversation with your hematologist is the right way to get answers specific to you. Some starting points worth raising:

What transfusion interval is right for my (or my child's) specific case, and why?
What hemoglobin level are we aiming to maintain between transfusions?
How will we monitor for iron overload as treatment continues?
Are there signs I should watch for between transfusions that would mean I need to come in sooner?
What are the long-term options beyond regular transfusion (e.g., transplant, emerging therapies)?

Frequently Asked Questions

How often do thalassemia patients need blood transfusions? It varies by type and severity. Thalassemia major typically requires transfusions every two to five weeks; thalassemia intermedia may need them only occasionally; thalassemia minor usually doesn't require transfusions. Your hematologist sets the exact schedule based on your individual case.

What happens if a thalassemia patient misses a transfusion? Delaying a scheduled transfusion can allow hemoglobin to drop further, which may cause increased fatigue, and in children, can affect growth and development over time. If a transfusion needs to be rescheduled, this should be discussed with your care team rather than skipped without guidance.

Do all thalassemia patients need transfusions? No. Transfusion needs depend on the type and severity of thalassemia. Many people with thalassemia minor (trait) never need transfusions, while those with thalassemia major typically need them regularly for life.

How long does a thalassemia transfusion take? A typical visit, including pre-transfusion testing, the infusion, and monitoring afterward, often takes a few hours, though this varies by clinic and individual case.

Can thalassemia be cured so transfusions are no longer needed? Bone marrow/stem cell transplant can be curative for some patients, and newer gene therapy approaches are also being studied and, in some regions, approved. These options aren't right or accessible for everyone. We explore this further in upcoming articles on transplant and gene therapy.

Medical Disclaimer

This article is for general educational purposes only and does not constitute medical advice. Transfusion schedules, hemoglobin targets, and management of any transfusion-related symptoms should always be determined by your hematologist or treating care team based on your individual health status. If you experience symptoms during or after a transfusion, contact your care team or seek emergency care as appropriate.

Sources

National Heart, Lung, and Blood Institute (NHLBI) — Thalassemia treatment information
Thalassemia International Federation — Guidelines for the Clinical Management of Transfusion Dependent Thalassaemia
Cooley's Anemia Foundation — Patient education materials on transfusion therapy
American Academy of Family Physicians (AAFP) — Thalassemia overview and management

Reviewer Flags (pending hematologist sign-off)

Transfusion interval ranges ("every two to five weeks" for thalassemia major) — verify against current TIF guidelines and confirm this range is still accurate/current
General statement on hemoglobin targets between transfusions — needs confirmation this is described accurately without giving specific numeric targets
Description of typical transfusion visit duration — verify this is a reasonable general range across clinical settings
Confirm description of pre-transfusion testing procedure is accurate and not overly specific/prescriptive

Living With Thalassemia Major: A Day-to-Day Guide

2026-07-27T18:34:48.745+05:30

Most articles about thalassemia major talk about it as a condition — what causes it, how it's classified, what the long-term outlook looks like. Fewer talk about what a Tuesday actually looks like when you're managing it. This is meant for that gap: for patients living with it day to day, and for the parents, partners, and caregivers building a life around it alongside them.

What "Living With Thalassemia Major" Actually Means, Day to Day

Thalassemia major — sometimes called Cooley's anemia — is the most severe form of beta-thalassemia, and it requires ongoing medical management rather than a one-time treatment. In practical terms, that means two things shape daily life more than anything else: a transfusion schedule, and the chelation routine that goes with it.

Blood Transfusions: Building a Life Around a Schedule

For most people with thalassemia major, regular blood transfusions aren't optional — they're what keeps hemoglobin at a level that allows for normal energy, growth, and organ function. Transfusions are typically needed every two to four weeks, and for many people, that becomes as routine as any other recurring medical appointment, if not quite as simple. Clinical guidance for patients recommends sticking to one transfusion center where possible, since consistency in blood matching, staff familiarity, and record-keeping all make the process smoother over time.

The transfusion itself usually takes a few hours, which means the day of a transfusion often gets built around it — work or school schedules shift, and many patients describe learning to plan the rest of their week around how they'll feel before and after.

Iron Chelation: The Routine Behind the Routine

Here's the part that surprises people who are new to thalassemia major: the transfusions themselves aren't the only ongoing commitment. Every transfusion adds iron to the body, and because the body has no natural way to remove excess iron, that iron accumulates in organs like the heart, liver, and endocrine glands over time. Left unmanaged, this iron overload is one of the more serious long-term risks of the condition.

That's where chelation therapy comes in — medication that helps the body remove excess iron before it causes organ damage. Depending on the specific medication, this can mean a daily pill or an injection delivered under the skin, and adherence to this routine is described by clinicians as one of the most important factors in long-term health outcomes. It's also, understandably, one of the harder parts of the routine to stay consistent with over months and years — which is exactly why many patients say having a stable daily habit (same time, same place, tied to something else you already do) makes more difference than willpower alone.

(Reviewer note: keep this section general — avoid naming specific chelation drugs or dosing schedules, since that crosses into treatment-specific guidance.)

Energy, Fatigue, and Planning Around Them

Even with a consistent transfusion schedule, energy levels for many people with thalassemia major follow a predictable rhythm: higher in the days right after a transfusion, gradually lower as the next one approaches. This isn't a sign that something's going wrong — it's a known pattern that many patients learn to plan around rather than fight. Scheduling demanding tasks, travel, or big social commitments earlier in the transfusion cycle, and building in more rest as the next one approaches, is a strategy many patients describe using instinctively once they recognize the pattern.

School, Work, and Everyday Responsibilities

A thalassemia major diagnosis does not mean school or a career is off the table — plenty of people manage both while living with the condition. What it usually does mean is a bit more communication and planning than the average student or employee needs:

Letting a school or employer know about the recurring transfusion schedule, so absences are expected rather than a surprise each time
Building in flexibility around the days immediately following treatment, when fatigue tends to be more noticeable
Having a plan for sick days or infections, since the immune considerations around transfusion and, in some cases, spleen removal, mean illnesses may need closer attention than they would otherwise

None of this has to mean under-performing at school or work — it usually just means the schedule looks a little different than a typical nine-to-five, and that's worth normalizing rather than hiding.

Travel and Life Outside the Regular Schedule

Travel is absolutely possible with thalassemia major, but it takes more coordination than it does for most people. Clinical guidance for patients recommends coordinating travel plans with the transfusion schedule in advance, rather than trying to receive a transfusion somewhere unfamiliar, particularly in places where blood supply safety standards may differ. For anyone who has had a splenectomy, carrying antibiotics while traveling is also a commonly recommended precaution, in case of fever or infection while away from a regular care team.

None of this rules out travel, study abroad, or relocating for work — it just means those plans usually start with a phone call to your hematology team, not an afterthought.

The Emotional Side of a Lifelong Condition

It's worth naming directly: managing a chronic, lifelong condition that requires this much ongoing coordination is emotionally demanding, not just logistically demanding. Feeling frustrated by the schedule, tired of the routine, or occasionally wanting a break from all of it is an extremely common experience among people managing thalassemia major — not a sign of failing to cope well. Many patients describe cycles of adjusting to the routine, feeling stable for a while, and then needing to re-adjust again after a life change like starting college, a new job, or a relationship.

This is a big enough topic that it deserves its own space — we go into coping strategies and mental health support in more depth separately.

Building a Support System

One consistent theme across patient accounts and clinical literature is that people managing thalassemia major do better, by their own account and by measurable health outcomes, when they're not managing it entirely alone. That support can look like:

A stable, ongoing relationship with one hematology team, rather than piecing care together from different providers each time
Connection with organizations built specifically around thalassemia, which can offer both practical guidance and a sense of shared experience
Family, friends, or a partner who understand the schedule well enough that it doesn't need to be re-explained every time

If you're newly navigating this, know that there is a well-established, decades-old community and body of medical support built specifically around this condition — you are not starting from zero.

FAQ

How often do people with thalassemia major need transfusions? Typically every two to four weeks, though the exact interval depends on individual factors your hematologist will determine.

Can someone with thalassemia major live a normal life? Yes, with modern transfusion and chelation care, many people with thalassemia major attend school, build careers, travel, and live well into adulthood — though it does require ongoing medical coordination.

Is chelation therapy done every day? Often, yes, depending on the specific medication prescribed — some are taken daily by mouth, others are delivered differently. Your hematologist will determine the right regimen for you.

What is the life expectancy for thalassemia major? Outcomes have improved substantially over recent decades with modern transfusion and chelation care, though individual outlook depends on factors like access to consistent treatment and how well iron overload is managed. (Reviewer note: consider linking to the dedicated life-expectancy post, scheduled for Week 8, rather than citing a specific number here.)

Can people with thalassemia major work full-time or attend school normally? Generally yes, with some planning around the transfusion schedule and recovery days — many people describe this becoming routine over time rather than a constant disruption.

This article is for general information and is not a substitute for professional medical advice. Treatment schedules, chelation regimens, and care decisions should always be made with your hematology team, based on your specific health status.

Reviewer flag: ⚠️ Recommend hematologist review before publishing — specifically the transfusion frequency range, the general chelation description (confirm no drug-specific dosing has crept in), and the life expectancy FAQ answer.

Sources consulted

CDC — "Treatment of Thalassemia" (cdc.gov)
Cooley's Anemia Foundation — thalassemia.org
City of Hope — "Thalassemia Treatment: Transfusions, Chelation Therapy & More"
NCBI Bookshelf — "General Health Care and Lifestyle in Thalassaemia," Guidelines for the Clinical Management of Thalassaemia
Hematology-Oncology Associates of CNY — "Treatment of Thalassemias"

Thalassemia Diagnosis: Tests, Blood Work & What Results Mean

2026-07-27T05:50:47.071+05:30

If you're reading this, there's a good chance a blood test just came back with something unexpected — a low MCV, a note about your red blood cells, or a doctor who mentioned the word "thalassemia" and moved on before you could really ask what it meant. That gap, between hearing the word and understanding what's actually being tested, is where a lot of anxiety lives. This is meant to close that gap.

Thalassemia is rarely diagnosed with a single test. It's usually a sequence — one result prompting the next — and knowing the order helps the whole process feel less like a black box.

Why a Routine Blood Test Is Often Where This Starts

Most people first encounter thalassemia not because they went looking for it, but because it showed up as a side finding. A pre-marital screening, a prenatal visit, a routine physical, or an unrelated illness can all trigger a standard blood test that flags something worth a second look. A complete blood count is typically the first test ordered, since it measures hemoglobin levels and the number and appearance of red blood cells — and people with thalassemia generally have fewer healthy red cells and lower hemoglobin than expected.

The Complete Blood Count (CBC): The First Clue

The CBC is the test almost everyone has had at some point — it's part of routine checkups and pre-op screening. For thalassemia, the numbers that matter most aren't just your hemoglobin level, but the size and shape of your red blood cells.

What Is MCV (Mean Corpuscular Volume)?

MCV measures the average size of your red blood cells. In thalassemia, red blood cells are typically smaller than normal — a pattern doctors call "microcytic." Thalassemia is generally suspected when microcytic anemia shows up alongside a normal or elevated ferritin (iron storage) level, since that combination points away from simple iron deficiency.

Why a Low MCV Doesn't Automatically Mean Thalassemia

This is worth repeating clearly: a low MCV is a prompt for more testing, not a diagnosis on its own. Clinical guidance recommends following up a low MCV with a hemoglobin electrophoresis test, and doing the same for people from backgrounds where thalassemia is more common, including Mediterranean, Middle Eastern, African, West Indian, and Southeast Asian populations. If you're in Sri Lanka, where thalassemia carrier rates are relatively high, this is exactly the kind of result a doctor is likely to follow up on.

Hemoglobin Electrophoresis and HPLC: Confirming What Kind

If the CBC raises a flag, the next step usually looks directly at the hemoglobin itself, rather than just the cells carrying it.

What These Tests Actually Measure

Hemoglobin electrophoresis and high-performance liquid chromatography (HPLC) separate out the different types of hemoglobin in your blood, measuring the proportions of hemoglobin A, A2, F, and other variants. These are considered the most reliable methods available for confirming a hemoglobin disorder.

Making Sense of HbA, HbA2, and HbF

You don't need to memorize hemoglobin biochemistry to understand your results — you mainly need to know what a pattern shift signals:

HbA is the main, "typical" adult hemoglobin.
HbA2 and HbF are minor components in healthy adults, but their proportions often shift in thalassemia.

In beta-thalassemia specifically, the classic pattern is an increase in HbA2, sometimes along with an increase in HbF. A report showing elevated HbA2 alongside a low MCV is one of the more recognizable fingerprints of beta-thalassemia trait — but exact cutoff values vary somewhat by lab and population, so this is a conversation for your hematologist rather than a comparison against a generic number online.

The Mentzer Index: A Quick Screening Clue, Not a Diagnosis

You may come across the term "Mentzer index" if you've searched your own lab results. It's a simple ratio — MCV divided by red blood cell count — that labs sometimes use as a fast screening clue to help separate thalassemia trait from iron deficiency anemia, since the two can look similar on a basic CBC.

It's a useful screening tool, but it isn't a confirmed diagnosis on its own, and it's not something to calculate yourself as a substitute for your care team's interpretation of the full picture.

Genetic Testing: When It's Needed and What It Confirms

Electrophoresis and HPLC can strongly suggest thalassemia, but they don't always tell the whole story — especially for alpha-thalassemia, or when results sit in a borderline range. Genetic testing is often needed to confirm a diagnosis definitively. This matters most for:

Family planning and carrier confirmation, especially before pregnancy
Distinguishing between similar-looking hemoglobin variants
Confirming a diagnosis in newborns or very young children, whose hemoglobin patterns are still shifting naturally in the first months of life

If you want the fuller picture on what genetic testing looks like before pregnancy specifically, [carrier screening before marriage or pregnancy] (link pending) walks through that process in more detail.

Telling Thalassemia Apart From Iron Deficiency Anemia

This distinction comes up constantly, because both conditions cause small, pale red blood cells, and both are common. The key differentiator is iron status: since thalassemia can look very similar to iron deficiency anemia on a basic CBC, doctors typically order a ferritin test to tell them apart. Low ferritin points toward iron deficiency; normal or high ferritin alongside microcytic anemia points more toward thalassemia.

This is exactly why iron supplements should never be started based on a low MCV alone — if the underlying cause is thalassemia rather than iron deficiency, iron supplementation isn't just unhelpful, it can contribute to iron overload over time. That decision should always sit with your doctor, based on your full test panel.

What Typically Happens After a Diagnosis

A confirmed thalassemia trait diagnosis, for most people, doesn't require ongoing treatment — it's information, not an illness in the day-to-day sense. A thalassemia major or intermedia diagnosis leads to a longer conversation with a hematologist about monitoring and, where relevant, treatment planning. Either way, the diagnostic pathway is designed to answer three questions in order: is this thalassemia, what type, and what does that mean for you and your family going forward.

FAQ

How is thalassemia diagnosed? Usually starting with a complete blood count that shows small, pale red blood cells, followed by hemoglobin electrophoresis or HPLC to identify the specific hemoglobin pattern, with genetic testing used to confirm the diagnosis when needed.

What blood test shows thalassemia? A CBC can raise suspicion through a low MCV, but hemoglobin electrophoresis or HPLC is the test that identifies the hemoglobin pattern associated with thalassemia.

What is a normal MCV level? Reference ranges vary slightly by lab, so ask your provider to interpret your specific result rather than comparing it to a general online range. (Reviewer note: insert a lab-verified reference range here before publishing.)

Can thalassemia be mistaken for iron deficiency anemia? Yes — both cause microcytic anemia, which is why a ferritin (iron) test is usually run alongside the CBC to tell them apart.

Is genetic testing necessary to confirm thalassemia? It's not always required, but it becomes important for confirming carrier status before pregnancy, distinguishing between similar hemoglobin variants, or clarifying a borderline result.

This article is for general information and is not a substitute for professional medical advice. If you or a family member have received an abnormal blood test result, please discuss the full results with your doctor or a hematologist, who can interpret your specific values in context.

Reviewer flag: ⚠️ Recommend hematologist review before publishing — specifically to verify reference ranges (MCV, HbA2 thresholds, Mentzer index cutoff) and confirm the iron-supplementation caution is phrased safely and accurately.

Sources consulted

NHLBI, NIH — "Thalassemia: Diagnosis" (nhlbi.nih.gov)
American Academy of Family Physicians — "Alpha- and Beta-thalassemia: Rapid Evidence Review" (aafp.org)
NCBI Bookshelf / StatPearls — "Laboratory Evaluation of Alpha Thalassemia" and "Laboratory Evaluation of Beta Thalassemia"
NCBI Bookshelf / GeneReviews — "Beta-Thalassemia"
UCSF Northern California Comprehensive Thalassemia Center — "Symptoms & Diagnosis"

Alpha vs Beta Thalassemia: What's the Difference?

2026-07-19T19:07:51.455+05:30

If you've been told you or your child has "thalassemia," one of the first things worth understanding is which kind. Alpha and beta thalassemia aren't just two names for the same condition — they involve different genes, different inheritance math, and a different range of possible severity. This post breaks down the basics of thalassemia into the alpha/beta distinction specifically, so you know what questions to ask next.

The Short Answer

Both alpha and beta thalassemia happen when the body can't make enough of one part of hemoglobin, the protein in red blood cells that carries oxygen. The difference comes down to which building block is affected:

Alpha thalassemia — affects production of the alpha-globin chain, controlled by four genes (two on each copy of chromosome 16).
Beta thalassemia — affects production of the beta-globin chain, controlled by two genes (one on each copy of chromosome 11).

That difference in gene count — four genes for alpha versus two for beta — is the reason alpha thalassemia has more possible severity levels than beta thalassemia does.

Alpha Thalassemia: How Many Genes Are Affected Determines Severity

Because there are four alpha-globin genes total, alpha thalassemia has four recognized levels of severity depending on how many of those genes are missing or non-functioning:

Genes affected	Name	What it looks like
1 of 4	Silent carrier	No symptoms; blood tests often normal
2 of 4	Alpha thalassemia trait (minor)	Usually no symptoms; smaller-than-normal red blood cells
3 of 4	Hemoglobin H disease	Moderate anemia, enlarged spleen, lifelong monitoring
4 of 4	Alpha thalassemia major (Hb Bart's)	Incompatible with life; typically results in pregnancy loss or stillbirth

This step-by-step scaling is specific to alpha thalassemia, because losing one gene out of four is a much smaller functional hit than losing one gene out of two.

Beta Thalassemia: Fewer Genes, Fewer Categories

Beta-globin is controlled by only two genes, so beta thalassemia has fewer possible combinations:

Genes affected	Name	What it looks like
1 of 2	Beta thalassemia trait (minor)	Usually no symptoms or very mild anemia
2 of 2	Beta thalassemia intermedia or major	Ranges from moderate anemia with occasional transfusions (intermedia) to severe anemia requiring lifelong regular transfusions (major, also called Cooley's anemia)

Whether someone with two affected beta genes ends up with intermedia or major depends heavily on which mutations they inherited — some allow a small amount of beta-globin production, others allow essentially none, and that difference in degree is what separates the two.

Can Someone Have Both?

Yes — and this is one of the more interesting parts of thalassemia genetics. Research has found that inheriting an alpha-globin gene change alongside beta thalassemia can actually make beta thalassemia less severe, because it helps rebalance the ratio between alpha and beta chains that the disease disrupts in the first place. This is why two people with what looks like the same beta-globin mutation can sometimes have noticeably different symptoms — their alpha-globin genes may be quietly doing some of the compensating.

Why the Distinction Matters for You

If you've had a blood test suggesting thalassemia trait, knowing whether it's the alpha or beta form matters for a few practical reasons:

Different confirmation tests. Beta thalassemia trait usually shows up clearly on hemoglobin electrophoresis or HPLC. Alpha thalassemia trait often requires genetic testing to confirm, since standard blood tests don't always distinguish it as clearly. [LINK PENDING — see our upcoming post on thalassemia diagnosis and blood work.]
Different reproductive math. If you and a partner are both carriers, the type matters — two beta thalassemia trait carriers face the classic 25% chance of a child with beta thalassemia major, while two alpha thalassemia trait carriers (each missing 2 of 4 genes) face a risk of Hemoglobin H disease or, in some combinations, Hb Bart's, which is life-threatening in pregnancy.
Different day-to-day outlook. Beta thalassemia major requires regular blood transfusions from early childhood. Hemoglobin H disease, the more common serious form of alpha thalassemia, usually involves moderate anemia and monitoring rather than routine transfusions, though this varies by individual.

Frequently Asked Questions

Is alpha or beta thalassemia more common? Both are common globally, though which one predominates varies by region and population — alpha thalassemia carrier rates are especially high across parts of Southeast Asia, while beta thalassemia is widespread across the Mediterranean, Middle East, and South Asia, including Sri Lanka.

Is alpha thalassemia worse than beta thalassemia? Neither is uniformly "worse" — it depends on how many genes are affected. The mildest and most severe forms exist on both sides; alpha thalassemia's most severe form (Hb Bart's) is incompatible with life, while beta thalassemia's most severe form (major) is very serious but manageable with lifelong treatment.

Can you have both alpha and beta thalassemia? Yes. Co-inheriting changes in both types of genes is possible, and it often changes how severe the beta thalassemia symptoms are — sometimes making them milder.

Which chromosome is affected in alpha vs beta thalassemia? Alpha-globin genes are on chromosome 16 (four copies total). Beta-globin genes are on chromosome 11 (two copies total).

What is Hemoglobin H disease? It's the name for alpha thalassemia when 3 of the 4 alpha-globin genes are affected — it typically causes moderate hemolytic anemia and an enlarged spleen, and requires ongoing monitoring, though not always regular transfusions.

Medical disclaimer: This article is for general educational purposes only and is not a substitute for professional medical advice or diagnosis. If you have questions about a specific diagnosis or test result, please speak with a hematologist or your care team.

References:

Johns Hopkins Medicine — Alpha Thalassemia (condition overview).
American Academy of Family Physicians (AFP) — Alpha and Beta Thalassemia clinical review.
MedicineNet — What Is Alpha Thalassemia vs. Beta Thalassemia?
Peer-reviewed studies on alpha-globin gene modification of beta-thalassemia severity (PMC).

[Note for reviewer: severity category names (e.g., "Hb Bart's," "Hemoglobin H disease," "thalassemia intermedia") are used per the sources above; please confirm these align with current clinical terminology conventions.]

Thalassemia Carrier Screening: What to Expect Before Marriage or Pregnancy

2026-07-19T19:07:36.689+05:30

Finding out you're a thalassemia carrier can feel like a lot to take in, especially if it comes up right when you're planning a wedding or a pregnancy. The good news is that carrier screening itself is simple, low-risk, and gives you real information to plan around — rather than something to be afraid of. This post walks through what the screening actually involves, who it's for, and what your results mean in practical terms.

If you haven't yet read about how thalassemia is inherited, it's worth a look first — carrier screening will make a lot more sense once you understand that thalassemia only causes disease when a child inherits an altered gene from both parents. This post assumes that background and builds on it. For a broader look at the different types of thalassemia, see our pillar guide.

What Is Thalassemia Carrier Screening?

Carrier screening is a blood test (or short series of tests) that checks whether you carry a thalassemia gene change, even if you feel completely healthy. Most carriers — often called having "thalassemia trait" or "thalassemia minor" — have no symptoms at all and only find out through testing.

The point of screening isn't to diagnose an illness in you. It's to give you information about the chance that a future child could inherit thalassemia major, the more serious form of the condition, which only happens if both parents are carriers.

Why Screening Matters Before Marriage or Pregnancy

Thalassemia is inherited in an autosomal recessive pattern. In practical terms, that means if only one partner is a carrier, children are very unlikely to be born with thalassemia major — but if both partners carry the trait, there's a 1-in-4 (25%) chance with each pregnancy that a child will inherit thalassemia major, and a 1-in-2 chance the child will be a carrier like the parents.

Knowing this before marriage or before trying to conceive gives couples time to make informed, unpressured decisions — rather than finding out during a pregnancy or after a child's diagnosis.

The "Safe Marriage" Approach in Sri Lanka

Sri Lanka has taken a somewhat different path from countries where prenatal testing and selective termination are part of prevention programs. Because termination of pregnancy isn't legally permitted here, Sri Lanka's national thalassemia prevention program has instead promoted the idea of a "safe marriage" — a union where at least one partner is confirmed not to be a carrier. The approach relies on voluntary premarital screening, ideally done well before a couple is engaged, so that carrier status can be one factor among many in deciding who to marry — not a crisis discovered afterward.

Sri Lanka has run screening programs since around 2018 through centers in high-prevalence areas including Kurunegala, Ragama, Anuradhapura, Badulla, and Kandy, with funding from the Ministry of Health, though researchers have noted the program has lacked central coordination and complete data collection. Screening rates and program structure can change, so if you're in Sri Lanka, it's worth contacting the National Thalassaemia Centre in Kurunegala or the Thalassaemia Care Centre at North Colombo Teaching Hospital, Ragama, directly for current information on where and how to get tested.

Who Should Consider Getting Screened

Screening is especially worth considering if:

You or your partner have a family history of thalassemia or unexplained anemia
You belong to a population group with historically higher carrier rates (South Asian, Mediterranean, Middle Eastern, and Southeast Asian backgrounds all have elevated rates)
You're planning marriage or a pregnancy and want to know your carrier status in advance
A routine blood test has ever shown small red blood cells (low MCV) that wasn't explained by iron deficiency

Even without any of these factors, screening is reasonable for anyone planning a family who wants to rule it out, particularly in regions like Sri Lanka's North Western, North Central, and Central provinces, where thalassemia has been identified as intermediately prevalent, with around 3,500 patients identified nationally.

What the Screening Process Involves

Carrier screening is a straightforward blood draw — no special preparation, fasting, or invasive procedure required. It usually happens in stages:

Step 1: Complete Blood Count (CBC)

This first, routine test looks at red blood cell size (MCV) and hemoglobin content (MCH) — values that tend to be lower than normal in thalassemia carriers, even though their overall hemoglobin level may look otherwise unremarkable.

Step 2: Hemoglobin Electrophoresis or HPLC

If the CBC suggests something worth investigating further, the next step is a test that separates and measures different types of hemoglobin in the blood — using methods such as HPLC or capillary electrophoresis to measure HbA2 and HbF levels. Beta thalassemia carriers are generally identified this way, through red-cell measurements and hemoglobin fraction analysis, without needing molecular testing.

Step 3: Genetic (DNA) Testing, When Needed

Alpha thalassemia carrier status, by contrast, typically does require molecular/genetic testing to confirm, since it doesn't always show up clearly on standard blood tests the way beta thalassemia trait does. Genetic testing may also be recommended if initial results are ambiguous, or to identify the exact gene mutation once someone is confirmed to be a carrier.

Understanding Your Results

There are broadly three outcomes:

Not a carrier — no thalassemia gene changes detected.
Carrier (trait/minor) — you carry one altered gene. You're almost always healthy and don't need treatment, but this is the information that matters for family planning.
Thalassemia major or intermedia — rare to discover this way in adulthood, since more significant forms are usually identified in childhood, but it's part of what the test can reveal.

If you're found to be a carrier, the single most useful next step is finding out your partner's status too — one carrier alone is not a cause for concern, but two carriers together changes the picture for future pregnancies.

If Both Partners Are Carriers: What Are the Options?

This is a deeply personal decision, and there's no single "right" answer — but here's what genetic counseling typically covers so you know what to expect from that conversation:

Understanding the actual probabilities involved (25% chance of thalassemia major per pregnancy, not a certainty)
Reviewing options such as prenatal genetic testing during pregnancy, or preimplantation genetic diagnosis combined with IVF for couples who want to avoid the possibility of an affected pregnancy altogether
Discussing what life with thalassemia major actually looks like today, given how much treatment has advanced
Deciding, without pressure, what feels right for your own circumstances, values, and beliefs

We're not able to give guidance on which option is "best" — that's exactly what a genetic counselor or hematologist is trained to walk you through, and it's a conversation worth having with a professional rather than deciding alone based on general information online. [LINK PENDING — see our upcoming post on thalassemia and pregnancy for more on prenatal options.]

Where to Get Screened

If you're in Sri Lanka, screening is available through:

National Thalassaemia Centre, Teaching Hospital, Kurunegala
Thalassaemia Care Centre, North Colombo Teaching Hospital, Ragama/Kadawatha

Availability, referral requirements, and cost can vary and change over time, so it's best to call ahead and confirm current details rather than relying on any single source, including this post.

Frequently Asked Questions

Is thalassemia carrier screening mandatory before marriage in Sri Lanka? No — Sri Lanka's national program depends on voluntary screening rather than a legal requirement, unlike some countries (such as parts of the Middle East) where premarital testing is mandated by law.

Can two thalassemia carriers get married? Yes, legally and personally that's entirely a couple's choice. Carrier status affects the odds for future children, not whether two people can or should marry — many carrier couples go on to have healthy or carrier (rather than thalassemia major) children, and options like prenatal testing exist for those who want more certainty.

What blood test detects thalassemia trait? A CBC is usually the first clue (low MCV/MCH), followed by hemoglobin electrophoresis or HPLC to confirm beta thalassemia trait, or genetic testing to confirm alpha thalassemia trait.

Does having thalassemia trait affect my own health? Most carriers are asymptomatic and live entirely normal, healthy lives. Thalassemia trait is not the same as thalassemia major, and typically doesn't require monitoring or treatment beyond the initial diagnosis.

How much does thalassemia screening cost? This varies by country, clinic, and whether it's offered through a public health program or private lab — we'd rather not guess at a figure here, so it's best to check directly with your nearest screening center for current pricing.

Medical disclaimer: This article is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or genetic counseling. If you're considering carrier screening or have questions about your results, please speak with a hematologist, genetic counselor, or your care team.

References:

Mudiyanse RM, et al. "Safe Marriages" for Thalassaemia Prevention: A KAP Survey in Sri Lanka. Translational Biomedicine, 2015.
Amarasinghe N, et al. Redesigning New Policy Options for Thalassemia Prevention in Sri Lanka. Thalassemia Reports, 2022.
Hemal's Adolescent and Adult Thalassaemia Care Centre, University of Kelaniya — Thalassaemia in Sri Lanka.
American College of Obstetricians and Gynecologists (ACOG) — Carrier Screening for Genetic Conditions.
Thalassaemia International Federation — 2021 Guidelines for the Management of Transfusion-Dependent Thalassemia.
EMQN Best Practice Guidelines — Prevention and Diagnosis of Haemoglobinopathies.
The ObG Project — Beta Thalassemia: Screening and Key Points.

[Note for reviewer: all cited figures and program descriptions above are drawn directly from the sources listed; none have been estimated or invented. The Sri Lanka program details in particular should be reviewed for currency, since screening infrastructure and center details can change.]

Thalassemia Symptoms in Children vs. Adults: What to Watch For at Every Stage

2026-07-13T22:40:09.400+05:30

If you're reading this because a blood test came back with unexpected results — for your child, yourself, or someone you love — one of the first questions is usually simple: what does this actually feel like, and when?

The honest answer is: it depends. Thalassemia isn't one experience. Two people with the same diagnosis on paper can have very different lives, and the same person's symptoms can look different at age 2, 15, and 40. This guide walks through how symptoms tend to show up at each stage, so you know what's typical, what's worth a call to the doctor, and what's simply part of managing a lifelong condition.

For a refresher on the types of thalassemia mentioned here, see our complete overview of thalassemia and our guide to thalassemia minor vs. major.

Why Symptoms Vary So Much by Age

Thalassemia symptoms come from one root cause — reduced or abnormal hemoglobin production, which limits how well red blood cells carry oxygen. But how much that affects a person depends on the type and severity of thalassemia they have, and severity is closely tied to age of onset. The more severe forms tend to announce themselves early, often before a child's second birthday, while milder forms may stay silent for decades or never cause noticeable symptoms at all.

Symptoms in Infants and Young Children

Thalassemia Major (Cooley's Anemia)

This is the form most likely to cause visible symptoms early. According to the National Heart, Lung, and Blood Institute (NHLBI), children with more serious types of thalassemia often develop symptoms by around age 2, and many of the most serious forms are picked up through newborn screening before symptoms even appear.

When symptoms do show up in infancy, they commonly include:

Pale skin, or yellowing of the skin and eyes (jaundice)
Poor feeding and slow weight gain
Irritability or unusual fussiness
A swollen abdomen, caused by an enlarged spleen or liver
Dark urine

Left unmanaged, these can progress to more serious issues — including stunted growth and complications affecting the heart, liver, and spleen — which is exactly why early diagnosis and ongoing care from a pediatric hematologist matter so much.

Thalassemia Intermedia

Symptoms of thalassemia intermedia tend to appear later than major and are usually milder day-to-day, but they still add up: pale or yellowish skin, an enlarged liver and spleen, gallstones, bone changes, and in some cases leg ulcers later in childhood or adolescence.

Thalassemia Minor (Trait)

This is the form most people never notice. Children with thalassemia minor may have mild anemia on a blood test but often have no symptoms at all — no fatigue, no visible signs, nothing that would prompt a visit to the doctor outside of routine bloodwork. It's frequently discovered by accident, or during carrier screening for family planning.

Adolescence: A Transition Period

For children with more significant forms of thalassemia who are receiving regular transfusions, adolescence is often when the cumulative effects of the condition — rather than new symptoms — start to matter more. Iron builds up in the body from years of transfusions, and this is often when doctors start watching more closely for early signs of iron-related complications, discussed below. This is also a stage where growth and puberty can be delayed compared to peers, which can be difficult emotionally even when it's medically expected.

Symptoms and Complications in Adults

Adults living with thalassemia, particularly thalassemia major or intermedia, are often managing two things at once: the underlying anemia, and the long-term effects of the disease and its treatment over time.

Iron Overload and Organ Effects

Because the body has no natural way to remove excess iron, and regular transfusions add iron faster than it can be processed, iron accumulation becomes a central concern in adulthood. Research has linked untreated iron overload to complications in the liver, heart, and endocrine glands. This is one of the most important reasons ongoing monitoring — not just symptom management — remains part of adult care.

Bone Health

Bone disease is common in adults with thalassemia major. Research published in Haematologica found that osteopenia and osteoporosis affect an estimated 40–50% of adults with thalassemia major, with contributing factors including anemia itself, iron overload, and hormone changes. Signs can include back pain, height loss, or fractures from minor injuries.

Endocrine and Fertility Effects

Iron overload can affect hormone-producing glands over time. A review published in Endocrine Reviews (Oxford Academic) notes that hypogonadism — reduced function of the reproductive glands — is the most common endocrine complication in transfusion-dependent thalassemia, with studies estimating it affects roughly a quarter to over half of patients in some cohorts. Thyroid function, blood sugar regulation, and growth hormone levels can also be affected, which is why adults with thalassemia are typically followed by an endocrinologist alongside their hematologist.

Emotional and Mental Health

It's worth naming something that often gets left out of symptom lists: living with a chronic condition since childhood, alongside physical complications that can appear in adulthood, has a real emotional weight. This isn't a symptom of thalassemia itself, but it's a common and valid part of the experience worth discussing with your care team.

Children vs. Adults: A Quick Comparison

	Children	Adults
Typical onset	Often by age 2 for severe forms	Ongoing management or newly surfacing complications
Common signs	Pallor, jaundice, poor growth, enlarged spleen	Fatigue, bone pain, hormone-related symptoms
Main clinical focus	Diagnosis, growth, starting treatment	Managing iron overload, organ monitoring
Mild forms (minor/trait)	Usually no symptoms	Usually no symptoms

When to Talk to a Doctor

Whether you're watching a child or managing your own health, it's worth reaching out to a hematologist if you notice new or worsening fatigue, unexplained pale skin or jaundice, bone pain, slowed growth in a child, or any new symptom that feels different from your usual baseline. Regular monitoring — even when you feel fine — is a core part of managing thalassemia at any age.

Medical Disclaimer

This article is for general educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Thalassemia symptoms and complications vary significantly between individuals. Please consult your hematologist or care team about any symptoms you or your child are experiencing, and before making any decisions about monitoring or care.

Frequently Asked Questions

What are the first signs of thalassemia in a baby? The earliest signs of more serious forms often include pale skin, poor feeding, slow weight gain, and a swollen abdomen, usually appearing by around age 2.

Does thalassemia minor (trait) cause symptoms? Usually not. Most people with thalassemia minor have mild anemia detectable only on blood tests, without noticeable symptoms.

Can thalassemia symptoms first appear in adulthood? Milder forms can go unnoticed for years and sometimes surface during routine bloodwork, pregnancy screening, or when investigating unrelated fatigue. More severe forms are almost always identified in early childhood.

What are the long-term complications of thalassemia major in adults? Common long-term concerns include iron overload affecting the heart and liver, bone density loss, and endocrine issues such as thyroid or reproductive hormone changes — all of which are actively monitored as part of ongoing care.

Are thalassemia symptoms different in children versus adults? Yes. In children, especially with severe forms, symptoms often center on growth, anemia, and organ enlargement. In adults, the focus shifts toward long-term complications from the condition and its treatment, such as iron overload and bone health.

Sources

National Heart, Lung, and Blood Institute (NHLBI) — Thalassemia: Symptoms, nhlbi.nih.gov/health/thalassemia/symptoms
Nationwide Children's Hospital — Beta Thalassemia in Children
Children's Health / Children's Minnesota — Thalassemia in Children
Haematologica — Iron overload and osteoporosis in thalassemia major patients, haematologica.org/article/view/7229
Endocrine Reviews (Oxford Academic) — Bone Disease in Thalassemia: A Molecular and Clinical Overview
American Society of Hematology (ASH) — Impact of Bone Disease and Pain in Thalassemia

2026-07-07T21:07:53.809+05:30

Thalassemia Minor vs Major: Key Differences Explained

"Minor" and "major" are two of the first words people hear after a thalassemia diagnosis or a carrier screening result — and they can sound almost casual, like the difference between a small problem and a big one. In reality, they describe very different genetic situations with very different day-to-day implications. Here's what actually separates them.

If you haven't already, our overview of what thalassemia is is a good starting point before this post — it covers the basics this one builds on.

The Short Version

The difference comes down to how many altered genes you've inherited, not how "bad" your case happens to be by chance.

Thalassemia minor (also called thalassemia trait): you've inherited one altered gene. This is a carrier condition that typically causes mild anemia symptoms, if any. NHLBI
Thalassemia intermedia: a middle ground, causing moderate anemia, usually from inheriting two altered genes with milder effects. NHLBI
Thalassemia major (Cooley's anemia, for the beta form): you've inherited two altered genes, one from each parent. This causes serious anemia symptoms and typically requires lifelong medical management. NHLBI

Thalassemia Minor: The Carrier Form

If you have thalassemia minor, you have one normal gene and one altered gene. Red blood cells are smaller than normal (microcytic) and lower in hemoglobin (hypochromic), but most people with thalassemia minor have no symptoms at all, or only mild, easy-to-miss ones. NHLBI

This is actually one of the more important — and more commonly misunderstood — parts of the thalassemia spectrum, because it's frequently mistaken for iron-deficiency anemia. The blood work can look superficially similar, but the underlying cause and the right response are completely different. Treating thalassemia minor as if it were iron deficiency can lead to unnecessary iron supplementation or unneeded diagnostic testing — which is exactly why an accurate diagnosis from a doctor, rather than a guess based on a single test result, matters here. NHLBINHLBI

People with thalassemia minor generally don't need ongoing treatment. The main relevance of a minor/trait diagnosis is for family planning — if you're a carrier and your partner is too, there's a meaningful chance of having a child with a more serious form. We'll cover exactly what that looks like in our upcoming carrier screening post.

Thalassemia Intermedia: The Middle Ground

Thalassemia intermedia doesn't get talked about as much as minor or major, but it's a real and distinct category — not just "a mild version of major." It was first identified decades ago, when clinicians needed a term for patients who were too severely affected to be called minor but too mildly affected to be called major. nih

People with thalassemia intermedia are grouped with what's sometimes called non-transfusion-dependent thalassemia — some have only mild anemia and need occasional transfusions, if any, while others present earlier in childhood with more noticeable effects on growth and development. Unlike thalassemia major, intermedia generally doesn't require regular lifelong transfusions, though iron overload and related complications can still develop over time, just more gradually. β-Thalassemia Intermedia: A Bird’s-Eye View +2

Because intermedia covers such a wide range of severity, it's genuinely one of the harder forms to generalize about — which makes an individual hematologist's assessment more important here than almost anywhere else on the spectrum.

Thalassemia Major: The Most Serious Form

Thalassemia major — also known as Cooley's anemia for the beta form — happens when both copies of the relevant gene are significantly altered. Without treatment, this leads to growth delays, paleness, jaundice, an enlarged liver and spleen, and skeletal changes from the bone marrow working in overdrive to compensate.

With proper care, the picture is very different. Regular blood transfusions are the main treatment for thalassemia major, giving the body red blood cells with healthy hemoglobin on an ongoing basis. A stem cell transplant is currently the only treatment that can potentially cure thalassemia, though it isn't the right option or available match for every patient. Because regular transfusions lead to iron building up in the body over time, iron chelation therapy — treatment to remove excess iron — becomes a standard part of managing thalassemia major long-term. nihnih

This is a lot to take in, and it's also, importantly, a manageable one. Thalassemia major is typically caught early — often through newborn screening — which means treatment usually starts before symptoms become severe.

Why the Distinction Actually Matters

Beyond the label itself, minor vs. intermedia vs. major changes real things: whether you need ongoing hematology care, whether family planning conversations matter, and what kind of monitoring makes sense going forward. If you're not sure which category applies to you or your child, that's worth confirming directly with your care team rather than inferring it from symptoms or a single test result — the categories can overlap enough at the edges that it takes clinical judgment, not just a lab value, to sort out.

Frequently Asked Questions

Is thalassemia minor dangerous?
Generally no — most people with thalassemia minor have mild symptoms or none at all and don't need treatment. Its main significance is usually for family planning, since two carriers can have a child with a more serious form.

Can thalassemia minor turn into major?
No. Your form of thalassemia is set by the genes you inherited at birth — it doesn't progress from minor to major over time the way some conditions worsen with age.

Is thalassemia intermedia the same as thalassemia major?
No, though there's overlap. Intermedia generally involves less severe anemia and, for many patients, doesn't require the same regular lifelong transfusion schedule that major typically does — though severity varies enough that it needs individual evaluation.

Does thalassemia minor need treatment?
Usually not. It's typically monitored rather than actively treated, though your doctor may still want to confirm the diagnosis to rule out other causes of similar blood test results.

This article is for general educational purposes and isn't a substitute for medical advice. If you have questions about your specific diagnosis or symptoms, please talk to your hematologist or care team.

Sources:

National Heart, Lung, and Blood Institute (NHLBI), NIH — Causes, Treatment
ScienceDirect Topics — Thalassemia Minor (clinical overview)
NCBI Bookshelf — Guidelines for the Clinical Management of Thalassaemia (Thalassaemia Intermedia)
PMC — β-Thalassemia Intermedia: A Bird's-Eye View

2026-07-06T22:31:45.581+05:30

What Is Thalassemia? Types, Causes & Complete Overview

If you've just been told you or your child has thalassemia — or that you're a carrier — you probably have more questions than answers right now. That's normal. Thalassemia is a lifelong condition, but it's also one of the most well-understood inherited blood disorders in medicine, and most people who have it go on to live full lives with the right care and support.

This guide is meant to be the starting point: a clear overview of what thalassemia is, why it happens, and what the different types mean. We'll link out to deeper posts on diagnosis, treatment, and daily life as they're published, so think of this as your home base.

What Is Thalassemia?

Thalassemia is an inherited blood disorder that affects how your body makes hemoglobin — the protein inside red blood cells that carries oxygen around your body. If you have thalassemia, your body doesn't produce enough normal hemoglobin, which means your red blood cells can't do their job as well, and you end up with fewer healthy red blood cells overall. This is a form of anemia, and depending on the type and severity, it can range from something you'd barely notice to a condition that needs lifelong medical care.

It's worth pausing on one distinction that trips a lot of people up: thalassemia is not the same as the anemia caused by low iron or poor diet. Iron-deficiency anemia happens because your body doesn't have enough iron to make hemoglobin. Thalassemia happens because of a genetic change that affects how hemoglobin is built, regardless of how much iron you have. This matters clinically too — taking iron supplements for thalassemia-related anemia, without a doctor's guidance, can actually cause harm rather than help, since iron overload is already a risk for many people with thalassemia. If you're not sure which one you're dealing with, that's a conversation for your doctor, not a guess based on symptoms alone.

What Causes Thalassemia?

The genetics — how it's passed down

Thalassemia is inherited, meaning it's passed from parent to child through genes. Hemoglobin is built from two types of protein chains, alpha and beta, and thalassemia happens when a genetic change disrupts the production of one of these chains.

Because it takes specific gene combinations to cause the more serious forms, thalassemia typically requires that both parents pass along an altered gene. If a child inherits just one altered gene, they usually become a carrier (sometimes called having "thalassemia trait" or "thalassemia minor") — generally with mild or no symptoms, but able to pass the gene to their own children. If a child inherits altered genes from both parents, the condition is usually more serious. <cite index="5-1">For beta thalassemia specifically, each child of two carrier parents has a 25% chance of inheriting two normal genes, a 50% chance of becoming a carrier, and a 25% chance of inheriting the more serious form</cite>. This is exactly why carrier screening before pregnancy matters so much — we'll cover that in a dedicated post.

Why some communities are affected more than others

<cite index="5-1">Thalassemia occurs most often among people of South Asian, Italian, Greek, Middle Eastern, and African descent</cite>, and it's also common throughout Southeast Asia. Researchers believe this pattern exists because carrying a single altered gene historically offered some protection against malaria — which is part of why these gene variants persisted in regions where malaria was widespread. <cite index="18-1">Globally, an estimated 270 million people carry a thalassemia or related hemoglobin gene variant, with somewhere around 80 to 90 million of those being beta thalassemia carriers specifically</cite>. If your family traces back to any of these regions, carrier screening is worth asking your doctor about — even if no one in your family has ever been diagnosed, since many carriers have no symptoms at all.

The Main Types of Thalassemia

Thalassemia isn't one single condition — it's a spectrum, and the terminology can be confusing at first.

Alpha thalassemia vs. beta thalassemia: <cite index="4-1">these are the two main types, and each depends on which part of the hemoglobin protein — alpha globin or beta globin — isn't being made correctly</cite>. Alpha thalassemia tends to be more common in people of Southeast Asian, South Asian, and African descent; beta thalassemia is more strongly associated with Mediterranean, Middle Eastern, and South Asian ancestry, though there's real overlap.

Trait / minor, intermedia, and major: within each type, severity is usually described in these terms:

Trait (minor): you carry one altered gene. <cite index="5-1">This usually causes only mild anemia symptoms, if any</cite>.
Intermedia: a moderate form, with anemia that's more noticeable but doesn't always require the same intensive treatment as major forms.
Major: the most serious form, <cite index="5-1">also known as Cooley's anemia when referring to beta thalassemia major</cite>, which typically requires regular blood transfusions and lifelong monitoring.

On the alpha thalassemia side specifically, the most serious form — where very little or no alpha globin is produced — is called Hb Bart syndrome, which is diagnosed before or at birth and is extremely serious; the milder serious form is hemoglobin H disease, which usually causes moderate to serious symptoms but is compatible with life. We'll go deeper on each of these distinctions, including alpha vs. beta specifically, in an upcoming post.

Common Symptoms

Symptoms vary enormously depending on type and severity — that's part of what makes thalassemia hard to explain in one sentence. <cite index="3-1">Some people have no symptoms at all, while children with more serious forms often start showing signs by around age two</cite>. When symptoms do appear, they can include:

Fatigue and weakness
Pale or yellowish skin (jaundice)
<cite index="3-1">A larger-than-normal spleen or liver, which can cause a swollen abdomen</cite>
Slow growth in children
Bone changes, particularly in the face, in more serious untreated cases

We're keeping this list general on purpose — symptoms in children and adults show up differently enough that it deserves its own post, which is coming soon.

How Thalassemia Is Diagnosed

Diagnosis usually starts with routine bloodwork — often a complete blood count (CBC) that turns up unusually small red blood cells (a clue doctors call microcytosis) — followed by more specific tests like hemoglobin electrophoresis, which identifies the different types of hemoglobin in your blood, and sometimes genetic testing to confirm which genes are involved. <cite index="3-1">More serious forms are frequently caught through routine newborn screening</cite>, which is part of why many parents first hear the word "thalassemia" in their baby's first days of life.

We'll walk through exactly what these tests measure and what your results might mean in a dedicated diagnosis post — this section is just the map, not the full territory.

How Thalassemia Is Managed

Management depends heavily on type and severity, and this is genuinely a conversation to have with a hematologist rather than something to self-manage from general information online. In broad strokes, care can include regular monitoring, blood transfusions for more serious forms, treatment to manage the iron overload that transfusions can cause over time, and in some cases, a bone marrow or stem cell transplant. Newer approaches, including gene therapy, are also changing what's possible for some patients.

We'll cover transfusions, iron overload management, and the latest treatment developments — including gene therapy — in their own posts, since each deserves real depth. If you take one thing from this section, let it be this: thalassemia management is highly individual, and your care team is the right source for decisions about your specific situation.

Living With Thalassemia

A diagnosis — for yourself or your child — can feel overwhelming at first. It's worth saying plainly: this is a condition people build full, meaningful lives around, not despite. Community matters here, and so does hearing from people who've actually lived it.

If you want to hear directly from someone managing thalassemia major day to day, Daniella Macolino's story is a good place to start, alongside Robert Mannino's patient profile — both offer a more personal window into what daily life can look like than a clinical overview ever could. We'll also be publishing a dedicated post on the emotional and mental health side of living with a chronic condition, because that part deserves just as much attention as the physical side.

Frequently Asked Questions

Is thalassemia the same as anemia? Not exactly. Thalassemia causes a type of anemia, but "anemia" is a broad term that covers many causes, including iron deficiency, which is a completely different issue with a different treatment approach.

Can thalassemia be cured? For most people, thalassemia is a lifelong condition managed through monitoring and treatment rather than cured. Bone marrow/stem cell transplant can be curative for some patients in specific circumstances, and gene therapy is an emerging option — both are worth discussing with a hematologist to understand if they're relevant to your situation.

Is thalassemia contagious? No. It's a genetic condition passed from parent to child — it can't be transmitted between people through contact, illness, or any other exposure.

Can two carriers have a healthy child? Yes — carrier status doesn't guarantee an affected child. As noted above, when both parents are carriers, there's still a meaningful chance of a child inheriting no altered genes or being a carrier without symptoms. Genetic counseling can walk through the actual odds for your specific situation.

Is thalassemia the same as sickle cell disease? No, though they're often mentioned together. Both are inherited hemoglobin disorders and both are more common in overlapping populations, but they involve different genetic changes and different disease patterns. We'll cover this comparison in more depth in an upcoming post.

This article is for general educational purposes and isn't a substitute for medical advice. If you have questions about a diagnosis, symptoms, or treatment, please talk to your hematologist or care team.

Sources:

National Heart, Lung, and Blood Institute (NHLBI), NIH — What Is Thalassemia, Causes, Symptoms
StatPearls (NCBI Bookshelf) — Thalassemia
Global Globin Network / PMC — carrier prevalence estimates

Three people with inherited diseases successfully treated with CRISPR

2020-06-23T21:50:00.000+05:30

By Michael Le Page

Sickle cell disease can distort red blood cells

Stocktrek Images, Inc/Alamy

Two people with beta thalassaemia and one with sickle cell disease no longer require blood transfusions, which are normally used to treat severe forms of these inherited diseases, after their bone marrow stem cells were gene-edited with CRISPR.

Result of this ongoing trial, which is the first to use CRISPR to treat inherited genetic disorders, were announced today at a virtual meeting of the European Hematology Association.

“The preliminary results… demonstrate, in essence, a functional cure for patients with beta thalassaemia and sickle cell disease,” team member Haydar Frangoul at Sarah Cannon Research Institute in Nashville, Tennessee, said in a statement.

Beta thalassaemia and sickle cell disease are conditions caused by mutations that affect haemoglobin, the protein that carries oxygen in red blood cells. Those with severe forms require regular blood transfusions.

However, a few people with the disease-causing mutations never show any symptoms, because they keep producing fetal haemoglobin in adulthood. Normally, fetal haemoglobin stops being produced soon after birth.

This discovery has inspired the development of treatments based on boosting fetal haemoglobin. In this trial, run by collaborating companies CRISPR Therapeutics and Vertex, bone marrow stem cells are removed from people and the gene that turns off fetal haemoglobin production is disabled with CRISPR.

The remaining bone marrow cells are killed by chemotherapy, then replaced by edited cells. This is done to ensure that new blood cells are produced by the edited stem cells, but the chemotherapy can have serious side effects including infertility.

The first two patients with beta thalassaemia no longer need blood transfusions since being treated 15 and five months ago. Nor does the patient with sickle cell disease, nine months after treatment.

The results are excellent, says Marina Cavazzana at the Necker-Enfants Malades Hospital in Paris, France, whose team has treated a 13-year-old boy with sickle cell disease using a different approach.

Although the three patients did experience some adverse effects due to the chemotherapy, the CRISPR gene editing appears safe. However, the patients may need to be monitored for the rest of their lives to be sure it has no adverse effects, says Cavazzana.

Altogether five people have now been treated. The trial was put on hold because of the coronavirus pandemic, but has now resumed.

Sign up to our free Health Check newsletter for a monthly round-up of all the health and fitness news you need to know

Longer Life Expectancy is Possible for Some Sickle Cell Disease Patients, Case Study Contends

2016-10-12T22:17:00.003+05:30

By Alice Melao

A published case study reports that patients with mildly symptomatic sickle cell disease (SCD) can exceed the U.S. median life expectancy of 47 years for patients with the disease if it is managed properly.

The report published in Blood, the Journal of the American Society of Hematology, “Case series of octogenarians with sickle cell disease,” analyzes four women diagnosed with milder forms of SCD who have lived as long as 86 years.

“For those with mild forms of SCD, these women show that lifestyle modifications may improve disease outcomes,” stated Samir K. Ballas, MD, professor emeritus in the Department of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, and principal author of the case study.

Ballas went on to explain that strong and long-term family support are important factors for the reported long life expectancy and high quality of life of the SCD patients. Moreover, strict adherence to medication and appointments also were reported as being highly important for the disease outcome.

MegaFood - Blood Builder, Promotes Healthy Blood Cell Production & Circulation, 90 Tablets (Premium Packaging)
“It is very likely that their healthy lifestyles were important contributors to their longevity,” said Ballas. “All of the women were non-smokers who consumed little to no alcohol and maintained a normal body mass index. This was coupled with a strong compliance to their treatment regimens and excellent family support at home,” he said.

The four cases studied in this report were considered by Ballas to be “desirable” disease states. “These women never had a stroke, never had recurrent acute chest syndrome, had a relatively high fetal hemoglobin count [which helps to prevent cells from sickling], and had infrequent painful crises. Patients like this usually — but not always — experience relatively mild SCD, and they live longer with better quality of life,” Ballas said.

Nevertheless, Ballas points out that this study included only four participants and all were women. Given so, more studies with a broader group of study is still required.

In summary, Ballas is hopeful that the stories of these four women can serve as examples for SCD patients. “I would often come out to the waiting room and find these ladies talking with other SCD patients, and I could tell that they gave others hope, that just because they have SCD does not mean that they are doomed to die by their 40s — that if they take care of themselves, and live closely with those who can help keep them well, that there is hope for them to lead long, full lives,” the author concluded.

Promising Gene Therapy For Sickle Cell Ready for Clinical Trial

2016-10-01T21:32:00.001+05:30

By Alexandra Anderson PhD

A new engineered gene therapy virus, inserted into blood stem cells and then transplanted into mice with sickle cell disease, markedly reduced red blood cell damage according to the study “Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype,” published in theJournal of Clinical Investigation.

A clinical gene therapy trial is expected in the coming year in which researchers will use a gene manipulated harmless virus to prevent the “sickling” of red blood cells. The new gene therapy is based on research going back to the 1980s which revealed that people with a milder form of sickle cell disease carried a fetal form of hemoglobin.

Hope and Destiny: The Patient and Parent's Guide to Sickle Cell Disease and Sickle Cell Trait
This form is present in the human fetus and normally tapers off after birth. It differs most from “adult” (beta) hemoglobin because it is able to bind oxygen to a larger extent and is not seen to “sickle”.

In later studies, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center researchers showed that suppressing a gene (BCL11A) that acts as an “off-switch” on the fetus hemoglobin, could restart the production again. With this approach the team was able to replace much of adult hemoglobin with the fetus form, in mice with sickle cell disease.

Dr. David A. Williams and colleagues from the center later adopted the approach.

“BCL11A represses fetal hemoglobin and also activates ‘adult’ hemoglobin, which is affected by the sickle-cell mutation,” Williams, the study’s senior author, said in a news release. “So when you knock BCL11A down, you simultaneously increase fetal hemoglobin and repress sickling hemoglobin, which is why we think this is the best approach to gene therapy in sickle cell disease.”

The new team tried to turn this insight into a therapy approach but they faced a problem. They discovered that the BCL11A gene also plays an important role in blood stem cells — which caused serious problems with the general blood development.

After some engineering in which the team used different gene techniques to silence the “switch-off” gene, without influencing the general blood development, they inserted the whole package into a lentivirus made for safe use in humans. Blood stem cells treated with this gene therapy were then successfully transplanted into mice and reduced the signs of sickle cell disease.

Additionally, in red blood cells from mice and four patients with the disease, the fetal hemoglobin surpassed the sickling “adult” hemoglobin, making up at least 80 percent of the total hemoglobin in the cell. According to the researchers, these results are more than enough to avoid the disease.

Williams believes this gene therapy approach will substantially increase the ratio of non-sickling versus sickling hemoglobin in patients, and his team is now taking the final steps toward FDA clearance for a clinical gene-therapy trial in sickle cell disease, that is expected to begin in early 2017.

New Biophysical Markers Could Help Develop Treatments for Sickle Cell Disease

2016-09-27T22:53:00.000+05:30

by Dr. Trupti Shirole

Sickle cell disease is an inherited blood disorder that affects an estimated 80,000 to 100,000 Americans each year. People with sickle cell disease have an abnormal form of hemoglobin, a protein found in red blood cells that carry oxygen throughout the body.

Normal red blood cells are flexible discs that easily bend and stretch to flow through the body's narrow blood vessels. In sickle cell disease, the abnormal hemoglobin forms fibers that cause the blood cells to take on a flattened, sickled shape and stiffen when they lose oxygen. This change in shape and rigidity causes the red blood cells to be stuck in the blood vessels and prevents the transport of oxygen to the surrounding tissue. This can cause anemia and extreme pain and impact the health of the body's tissue and organs.

Currently, hydroxyurea is the only FDA-approved drug for sickle cell disease. The drug reduces sickling in red blood cells and is used to treat pain and reduce the need for blood transfusions in some patients, but it does not work in all patients. Researchers have been divided over what mechanisms cause the drug to work. Some believe it works by reactivating fetal hemoglobin, which is better at transporting oxygen than the abnormal hemoglobin that causes sickling. Others believe it works by increasing the volume of red blood cells, reducing the concentration of sickle hemoglobin.
An interdisciplinary, international group of researchers has found new biophysical markers that could help improve the understanding of treatments for sickle cell disease, a step toward developing better methods for treating the inherited blood disorder.

"There is a critical need for patient-specific biomarkers that can be used to assess the effectiveness of treatments for sickle cell disease," said Subra Suresh, president of Carnegie Mellon University and co-author of the study. "This study shows how techniques commonly used in engineering and physics can help us to better understand how the red blood cells in people with sickle cell disease react to treatment, which could lead to improved diagnostics and therapies."

The findings from engineers, physicists and clinicians from Carnegie Mellon, the University of Pittsburgh, the Massachusetts Institute of Technology, Florida Atlantic University, Korea University, the Korea Advanced Institute of Science and Technology, and Harvard University will be published this week in the online early edition of the Proceedings of the National Academy of Sciences (PNAS).

In the current study, the international research team evaluated the biophysical properties - shape, surface area and volume - and biomechanical properties - flexibility and stickiness - of red blood cells under normal oxygenated conditions using electromagnetic waves to measure small differences in physical properties. The technique, known as common-path interferometric microscopy, allowed researchers to get a three-dimensional view of the cells.

Using blood samples from patients with sickle cell disease, the researchers separated red blood cells into four groups based on their density. Normal, disc-shaped red blood cells were the least dense, while severely sickled cells were the most dense. They then took samples from people receiving hydroxyurea treatment and those not receiving treatment. The red blood cells of those receiving treatment showed an improvement in all of the biophysical and biomechanical properties tested across all density levels. Furthermore, improvement in the physical properties of red blood cells of people treated with hydroxyurea correlated more with an increase in the red blood cell volume than with levels of fetal hemoglobin.

"Our findings shine a light on the mechanism behind hydroxyurea action, which has long been debated in the scientific community," said Ming Dao, principal research scientist in MIT's Department of Materials Science and Engineering and co-author of the study. "It's exciting to see that using the latest optical imaging tools, we can now confirm which one is the dominating mechanism. Understanding the key mechanism of action will allow us to explore novel and improved therapeutic approaches for sickle cell disease."

The researchers hope that these biophysical markers can be combined with biochemical and molecular-level markers to assess things like the severity of a patient's sickle cell disease, determine whether or not a patient will respond to hydroxyurea treatment and monitor the effectiveness of that treatment.

Sickle Cell Natural Healing: A Mother's Journey
Source: Eurekalert

Gene editing of blood stem cells can correct disease-causing mutations

2016-09-23T23:34:00.003+05:30

Recent advances in gene editing technology, which allows for targeted repair of disease-causing mutations, can be applied to hematopoietic stem cells with the potential to cure a variety of hereditary and congenital diseases. Gene editing can overcome many of the obstacles associated with gene addition therapies, but this young field still faces many challenges before it is ready for human testing, as discussed in a Review article published in Human Gene Therapy.

The article entitled "Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles" is part of a special joint issue on stem cell gene therapy in Human Gene Therapy and Stem Cells & Development guest edited by Luigi Naldini, MD, Scientific Director, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy. A special "upside-down" print issue will be distributed at ESGCT/ISSCR Florence 2016 in October.
Gene Editing, Epigenetic, Cloning and Therapy

Kyung-Rok Yu, Hannah Natanson, and Cynthia Dunbar, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, describe how earlier gene addition strategies and the hurdles they encountered have informed the current development of gene editing approaches. The authors present the state-of-the-art in gene editing technology and the potential to apply these novel techniques to repair genetic flaws in hematopoietic stem cells, which give rise to the different types of cells in blood, and then to test those strategies in human clinical trials.
"Gene editing is the hottest new technology in gene therapy. The use of this approach to genetically modify hematopoietic stem and progenitor cells is very promising, but requires a careful assessment," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "This mini-review by Dr. Dunbar's group at NIH provides a very insightful analysis of recent advances and current limitations of this approach

Smartphone App may offer needle free way to screen Blood for Anemia

2016-09-21T22:30:00.002+05:30

Carolina Henriques:

Engineers and computer scientists from the University of Washington (UW) have developed what they are calling a HemaApp, designed to detect hemoglobin concentration using simply a smartphone camera and a little extra lighting — rather than needles or an expensive, specialized machine.

Measuring hemoglobin, a protein found in red blood cells, is particularly important for people with anemia and other blood disorders, who require frequent blood draws. The app is also thought to detect abnormal hemoglobin properties, which could help screen for diseases such as sickle cell anemia.

Described in an article that won a ‘Best Paper’ award, HemaApp will be presented at the Association for Computing Machinery’s 2016 International Joint Conference on Pervasive and Ubiquitous Computing (UbiComp 2016), taking place on Sept. 15 in Germany.

Healthcare providers now measure hemoglobin levels by drawing blood with a needle or an intravenous line, or by using Masimo Pronto, an U.S. Food and Drug Administration (FDA)-approved device that measures hemoglobin noninvasively by clipping a sensor onto a person’s finger. The device, however, is too expensive for many medical facilities worldwide.

“In developing countries, community health workers have so much specialized equipment to monitor different conditions that they literally have whole bags full of devices,” Edward Wang, the study’s lead author and UW electrical engineering doctoral student, said in a press release. “We are trying to make these screening tools work on one ubiquitous platform — a smartphone.”

HemaApp works by analyzing the color of blood when light is shone from the phone’s camera — with a little help, for now, from external lighting — through a patient’s fingers, and then estimating hemoglobin concentrations. By analyzing how colors are absorbed and reflected across wavelengths, it can detect concentrations of hemoglobin and other components, like plasma.

HemaApp was tested in an initial trial including 31 patients. Requiring only one smartphone modification, HemaApp performed as well as the Masimo Pronto, the researchers said.

To make sure that the technology works on different skin tones and body masses, the team developed processing algorithms that use the patient’s pulse to differentiate between the properties of the patient’s blood and the physical aspects of the patient’s finger.

The UW team tested the app under three different scenarios: using the smartphone camera’s flash alone, in combination with a common incandescent lightbulb, and with a low-cost LED lighting attachment – additional light sources fall onto other sections of the electromagnetic spectrum that aren’t now found on all smartphone cameras.

“New phones are beginning to have more advanced infrared and multi-color LED capabilities,” said Shwetak Patel, the paper’s senior author and an endowed professor in Computer Science and Engineering and Electrical Engineering at UW. “But what we found is that even if your phone doesn’t have all that, you can put your finger near an external light source like a common lightbulb and boost the accuracy rates.”

In the initial studies, HemaApp’s hemoglobin measurements had a 69% correlation to a patient’s complete blood count (CBC) test, a 74% correlation when using a common incandescent light bulb, and an 82% correlation using a small circle of LED lights attached to the phone. Masimo Pronto scored an 81% correlation to the blood test.

Zahlers Iron Complex, Complete Blood Building Iron Supplement with Ferrochel, Easy on the Stomach Iron Pills with Vitamin C, Optimal Absorption, Kosher Certified Iron Vitamins, 100 Capsules

The app is not meant to replace blood tests, but results suggest that it could be an effective and affordable screening tool to determine if blood testing is needed. When used in anemia screening, HemaApp accurately identified 79% of the cases of low hemoglobin levels and 86% when aided with light sources.

“Anemia is one of the most common problems affecting adults and children worldwide,” said Doug Hawkins, a UW Medicine, Seattle Children’s Hospital, and Seattle Cancer Care Alliance pediatric cancer specialist. “The ability to screen quickly with a smartphone-based test could be a huge improvement to delivering care in limited-resource environments.”

MegaFood - Blood Builder, Promotes Healthy Blood Cell Production & Circulation, 90 Tablets (Premium Packaging) Further research steps include further testing of HemaApp to collect additional data and improve accuracy rates. The research project received financial assistance from the Washington Research Foundation.

Stem cell transplant cures children with sickle cell anemia, says Alberta hospital

2016-09-21T22:04:00.000+05:30

7 girls, 2 boys cured in what lead doctor considers unprecedented treatment

By Lisa Monforton,

Cardelia Fox has a tattoo on the inside of her right forearm with the words "Set free."

It's a reminder of how a cutting-edge transplant at the Alberta Children's Hospital cured her of sickle cell anemia and a life of hospital stays and blood transfusions.

The chronic genetic blood disorder caused Fox to have three childhood strokes — the first when she was only six months old. She would have two more at age six and 10.

Until the age of 17, she had been in and out of hospital and previously needed to have monthly life-saving blood transfusions.

The year Fox turned 17 she was one of the first patients to undergo the stem cell transplant procedure at the Alberta Children's Hospital.

The success of the procedure has captured interest from around the world, says Dr. Greg Guilcher, a pediatric oncologist who leads the sickle cell blood and marrow transplant program in Calgary.

Dr. Greg Guilcher is the lead doctor for the stem cell transplant procedure at Alberta Children's Hospital.

"To our knowledge, no one else is offering this protocol in children with sickle cell anemia," said Guilcher, who is also an assistant professor in the departments of oncology and pediatrics at the University of Calgary's Cumming School of Medicine.

What sets the Calgary procedure apart from other sickle cell anemia cures in young children is the lead up to the transplant.

"This protocol uses the 'lightest' doses of medication — no chemotherapy but immune suppressing drugs only, with a low dose of radiation," said Dr. Guilcher in a statement.

While the protocol was developed and is used in the U.S., Dr. Guilcher said he's not aware of any other hospital using it on children.

More exciting is the fact that there have been no incidents of stem cell rejection.

"We're getting phone calls and emails from around the world from interested parents and other doctors. We think we're ahead of the curve in offering this curative therapy as a standard of care."

Sickle cell anemia is a chronic illness where blood vessels can become blocked when blood cells change into a sickle shape, potentially affecting every organ and causing strokes, lung disease heart strain and spleen and bone damage. With advanced drug therapy treatment, life expectancy is 55- to 60-years-old.

The success of the procedure, which was first performed in Calgary in 2009, has cured seven girls and two boys to date.

Life-changing, says patient

"Before the stem cell transplant I felt like I was trapped," says Fox, whose sister Tamika Allen was a perfect match — a rare one in five occurrence within families. "Without this treatment I would likely still be at Foothills getting blood transfusions every month."

Tamika Allen, left, was a perfect stem cell match to her sister Cardelia Fox, which allowed her to have a procedure curing her of sickle cell anemia. (CBC)

Once Allen found out she was a full match, she didn't think twice about helping her sister.

Without a family match, the transplant procedure is generally considered too risky to perform.

"When we learned I was a match there was never any question of whether or not I'd do it," said Tamika, now 22. "Of course I'm going to do this for my sister. It was such a good feeling to be able to help make her life better — now I call her my mini-me."

Rising incidence in Canada

People of African descent are most often affected by sickle cell anemia. One parent can pass on the mutation and not cause the illness, but the illness results when both parents pass it on.

Fox's grandmother died at the age of 35 because of complications from the disease.

In 2008, the Sickle Cell Clinic at the children's hospital regularly treated 16 children.

Now there are more than 80, primarily because of immigration, says Dr. Mike Leaker. He is the head of the clinic, which sees patients from Alberta, Saskatchewan and eastern B.C.

"We now have some excellent medications that can change the course of the illness for many patients," said Leaker. "But a drug is still a treatment, not a cure. For families the word 'cure' is incredibly powerful."

Guilcher is expecting continued interest in the procedure from around the world

Sickle Cell Anemia: From Basic Science to Clinical Practice

Cure for sickle cell in adults validated

2016-09-17T22:07:00.000+05:30

Source:: University of Illinois at Chicago
Summary:: Physicians have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings. The new technique eliminates the need for chemotherapy to prepare the patient to receive the transplanted cells and offers the prospect of cure for tens of thousands of adults suffering from sickle cell disease.

Ieshea Thomas was the first adult to be cured of sickle cell disease with the chemotherapy-free procedure at UI Health.

Credit: Image courtesy of University of Illinois at Chicago

Physicians at the University of Illinois Hospital & Health Sciences System have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings.

The transplants were the first to be performed outside of the National Institutes of Health campus in Maryland, where the procedure was developed. Physicians there have treated 30 patients, with an 87 percent success rate. The results of the phase I/II clinical trial at UI Health, in which 92 percent of treated patients were cured, are published online in the journal Biology of Blood & Marrow Transplantation.
The new technique eliminates the need for chemotherapy to prepare the patient to receive the transplanted cells and offers the prospect of cure for tens of thousands of adults suffering from sickle cell disease.
About 90 percent of the approximately 450 patients who have received stem cell transplants for sickle cell disease have been children. Chemotherapy has been considered too risky for adult patients, who are often more weakened than children by the disease.
"Adults with sickle cell disease are now living on average until about age 50 with blood transfusions and drugs to help with pain crises, but their quality of life can be very low," says Dr. Damiano Rondelli, chief of hematology/oncology and director of the blood and marrow transplant program at UI Health, and corresponding author on the paper.
"Now, with this chemotherapy-free transplant, we are curing adults with sickle cell disease, and we see that their quality of life improves vastly within just one month of the transplant," said Rondelli, who is also the Michael Reese Professor of Hematology in the UIC College of Medicine. "They are able to go back to school, go back to work, and can experience life without pain."
Sickle cell disease is inherited. It primarily affects people of African descent, including about one in every 500 African Americans born in the U.S. The defect causes the oxygen-carrying red blood cells to be crescent shaped, like a sickle. The misshapen cells deliver less oxygen to the body's tissues, causing severe pain and eventually stroke or organ damage.
Sickle Cell Natural Healing: A Mother's Journey
Doctors have known for some time that bone marrow transplantation from a healthy donor can cure sickle cell disease. But few adults were transplanted because high-dose chemotherapy was needed to kill off the patients' own blood-forming cells -- and their entire immune system, to prevent rejection of the transplanted cells, leaving patients open to infection.
In the new procedure, patients receive immunosuppressive drugs just before the transplant, along with a very low dose of total body irradiation -- a treatment much less harsh and with fewer potentially serious side effects than chemotherapy.
Next, donor cells from a healthy and tissue-matched sibling are transfused into the patient. Stem cells from the donor produce healthy new blood cells in the patient, eventually in sufficient quantity to eliminate symptoms. In many cases, sickle cells can no longer be detected. Patients must continue to take immunosuppressant drugs for at least a year.
In the reported trial, the researchers transplanted 13 patients, 17 to 40 years of age, with a stem cell preparation from the blood of a tissue-matched sibling. Healthy sibling donor-candidates and patients were tested for human leukocyte antigen, a set of markers found on cells in the body. Ten of these HLA markers must match between the donor and the recipient for the transplant to have the best chance of evading rejection.
In a further advance of the NIH procedure, physicians at UI Health successfully transplanted two patients with cells from siblings who matched for HLA but had a different blood type.
In all 13 patients, the transplanted cells successfully took up residence in the marrow and produced healthy red blood cells. One patient who failed to follow the post-transplant therapy regimen reverted to the original sickle cell condition.
None of the patients experienced graft-versus-host disease, a condition where immune cells originating from the donor attack the recipient's body.
One year after transplantation, the 12 successfully transplanted patients had normal hemoglobin concentrations in their blood and better cardiopulmonary function. They reported less pain and improved health and vitality.
Four of the patients were able to stop post-transplantation immunotherapy without transplant rejection or other complications.
"Adults with sickle cell disease can be cured without chemotherapy -- the main barrier that has stood in the way for them for so long," Rondelli said. "Our data provide more support that this therapy is safe and effective and prevents patients from living shortened lives, condemned to pain and progressive complications."

Story Source:
The above post is reprinted from materials provided by University of Illinois at Chicago. The original item was written by Sharon Parmet. Note: Content may be edited for style and length.

Daniella Macolino a 24 year old actress who pursues her dreams each day while living, and thriving, with thalassemia major

2016-09-16T21:44:00.001+05:30

When I was four months old, my family and I were on vacation in Vermont when my mom noticed I was turning yellow after my older brother took me out in the snow. She overlooked it, thinking I may have just been tired from all the traveling and playing outside. But the next day I was looking worse with bags under my eyes, so my parents rushed me to the hospital. The doctor ran some tests and broke the news to my parents that I have thalassemia major, also known as Cooley’s Anemia. Not only would I need a blood transfusion right away, I would also need to continue receiving transfusions every two weeks for the rest of my life in order to survive.

My mother was born and raised in France, and she came to America not speaking any English. Neither of my parents had any knowledge that they carried the thalassemia trait and had never even heard of it before my diagnosis. Since then, my parents have become my biggest advocates and made sure I grew up with an amazing support system of friends and family. My siblings, Paul, Joseph, and Victoria, understand what I go through and don’t look at me any differently.
Living with thalassemia has been difficult, especially as a teenager. I wanted to be like my friends—go out and have sleepovers—but couldn’t because I had to be home to take my Desferal injection. This nightly routine requires me to sleep with a needle pumping medication into my body to remove the deadly iron buildup caused by receiving frequent blood transfusions. I hated it, and it was very inconvenient for me. It was frustrating waking up with bruises on my legs and arms from the needle being in all night.

Beyond that, it was hard trying to fit in while feeling so different because I had an illness and had to go to the hospital frequently. I only told a few of my closest friends that I had this disorder. Now that I am older and more confident, I am very open about sharing my experience with everyone. This illness isn’t going to define who I am, but it will make me stronger and I know that’s why people are inspired by my story!

Isabella's Journey: Her Battle with the Blood Disorder, Thalassemia Major.

The Cooley’s Anemia Foundation has been so amazing to me and my family. I can contact the Foundation anytime I have questions or need anything and they are there for me. The amount of gratitude I have for them, I can’t even put into words! I have been able to meet the most amazing people by attending Foundation conferences and other events. We are a true community, supporting each other’s passions, goals, and dreams.
It is so important to get involved with and support the Foundation, especially if you or someone you know has thalassemia. I know I can speak on behalf of patients like me when I say that getting involved is worth it because we are raising public awareness of our disorder as well as funds for medical research. One day, there will be a cure and I believe it will come sooner than expected!

“Choose a job you love, and you will never have to work a day in your life.” -Confucius
I believe that no matter what, everyone should follow their dreams and
no obstacle should stand in the way of accomplishing that! Those who know me know that I am pursuing an acting career and I have been for a while now. I don’t know exactly what it is about being in front of the camera or on stage that makes me feel amazing… but I know that I could not live without acting.
I’ve had to sacrifice so many things in order to keep doing what I love, but I’m no stranger to challenges! This is what I want to do and I will never give up. All the hard work is paying off because each year, I find myself doing better and better in my acting career. From January to May of this year I played a leading role in an independent feature film called The Prey—look out for it in October! And in August, I will be in a short horror film which I am really excited about. Tonight, I appear in an episode of The Perfect Murder on the ID channel. It is so crazy to even think that I have made it this far! Even though I put myself down every now and then thinking that I should be doing more, I am still really proud of what I have accomplished so far.
My advice to other thalassemia patients is to not look at yourself any differently than anyone else. Live your life day by day. Do what you love and don’t listen to anyone who puts you down, because at the end of the day you are a strong individual capable of doing what you want!
Just always remember to be safe and take care of yourself. It is important to be compliant by doing your chelation EVERY DAY and staying on schedule with blood transfusions. If you’re tired or feeling ill, don’t put it to the side! Your health comes first no matter what.
Thalassemia is rare and I know many people have not heard about it, but it is just as dangerous as any other chronic illness. Every patient is different and there is a wide range of complications. Please help us raise awareness and if you have never gotten your blood tested, visit your doctor to see if you carry the trait.

Scientists find new way to use CRISPR gene editing to help fix sickle cell disease

2016-09-16T21:23:00.005+05:30

An international team of scientists led by researchers at St. Jude Children's Research Hospital has found a way to use CRISPR gene editing to help fix sickle cell disease and beta-thalassemia in blood cells isolated from patients. The study, which appears online today in Nature Medicine, provides proof-of-principle for a new approach to treat common blood disorders by genome editing.
"Our approach to gene editing is informed by the known benefits of hereditary persistence of fetal hemoglobin," said Mitchell J. Weiss, M.D., Ph.D., chair of the St. Jude Department of Hematology and one of the study's lead authors. "It has been known for some time that individuals with genetic mutations that persistently elevate fetal hemoglobin are resistant to the symptoms of sickle cell disease and beta-thalassemia, genetic forms of severe anemia that are common in many regions of the world. We have found a way to use CRISPR gene editing to produce similar benefits."
Fetal and adult hemoglobin are two different molecular forms of the essential oxygen-carrying molecule in red blood cells. Hemoglobins are made up of different combinations of four molecular subunits. Sickle cell disease and beta-thalassemia are caused by mutations in a gene encoding an adult-expressed subunit termed "beta." Disease becomes apparent after birth as the levels of adult hemoglobin take hold and levels of fetal hemoglobin decline. These mutations can affect the survival of red blood cells and inhibit oxygen delivery to tissues, causing impaired function of different organs with devastating consequences for patients. Fetal hemoglobin lacks beta subunits and has gamma subunits instead. Thus, beta-thalassemia or sickle cell disease–associated mutations, which impair the production or function of the beta subunit, do not cause problems with fetal hemoglobin, which can transport oxygen effectively in adults.
Experts have known for some time that inhibiting or reversing "gamma-to-beta" switching of hemoglobin subunits can raise levels of fetal hemoglobin in adults and significantly ameliorate the debilitating symptoms of beta-thalassemia or sickle cell disease.

"Our work has identified a potential DNA target for genome editing–mediated therapy and offers proof-of-principle for a possible approach to treat sickle cell and beta-thalassemia," added Weiss. "We have been able to snip that DNA target using CRISPR, remove a short segment in a "control section" of DNA that stimulates gamma-to-beta switching, and join the ends back up to produce sustained elevation of fetal hemoglobin levels in adult red blood cells." When the scientists edited the DNA of blood-forming stem cells derived from patients with sickle cell disease, they were able to activate those genes and produce red blood cells that had enough fetal hemoglobin to be healthy.
Recently, scientists have used several gene editing approaches to manipulate blood-forming stem cells for the possible treatment of sickle cell disease and beta-thalassemia, including repair of specific disease-causing mutations and other strategies to inhibit gamma-to-beta switching. All of these approaches remain untested in patients.
"Our results represent an additional approach to these existing innovative strategies and compare favorably in terms of the levels of fetal hemoglobin that are produced by our experimental system," said Weiss. Using genome editing to restore the hereditary persistence of fetal hemoglobin is an attractive possibility, because it can be achieved relatively easily using current technologies. The condition is known to be benign in people who inherit similar naturally occurring mutations.
At this stage, the scientists emphasize that it is still too early to begin clinical trials of the new gene editing approach. The researchers want to refine further the gene editing process and perform other experiments to minimize potentially harmful off-target mutations before in-human clinical trials are considered. Additionally, it will be important to compare different approaches head-to-head to determine which one is safest and most effective.

Source:

St. Jude Children's Research Hospital

Pediatric sickle cell study stopped early due to positive results

2016-01-29T10:25:00.004+05:30

Hydroxyurea shown as viable option for some children with sickle cell anemia

Source:: Medical University of South Carolina
Summary:: For some children with sickle cell disease, the drug hydroxyurea is as effective as blood transfusions to reduce blood flow speeds in the brain, a national sickle cell disease study has found. Increased blood flows are a major risk factor for stroke in these children, report investigators.; FULL STORY

Pediatric/hematologist Dr. Sherron Jackson of the Medical University of South Carolina examines a patient with sickle cell disease.

Credit: Photograph by Sarah Pack, Medical University of South Carolina

Pediatric/hematologist Dr. Sherron Jackson of the Medical University of South Carolina examines a patient with sickle cell disease.

Credit: Photograph by Sarah Pack, Medical University of South Carolina

"It was a privilege to be a part of this well-designed and executed study. Russell Ware presented the results at the ASH meeting, and 18 years ago, almost to the day, I presented the STOP study results to the same meeting," said Robert J. Adams, M.D., study principal investigator, MUSC professor of neurosciences and director of the South Carolina Stroke Center of Economic Excellence. "That study showed how effective transcranial Doppler risk stratification, followed by regular red cell transfusions in those with high risk blood flow, can be in the prevention of stroke in these children. This became known as the STOP protocol and its wide adoption has been associated with a sharp drop in ischemic strokes in children with sickle cell disease. The drawback of indefinite transfusions however, was a limitation to wider use of the STOP protocol. This study shows that some children can be moved from transfusion to medication after at least a year. The combined understanding and evidence from these two studies brings us closer to achieving the National Institutes' goal of a 'stroke free generation' in sickle cell disease."

Standard treatment for children with sickle cell disease who are at high risk of stroke consists of regular blood transfusions. Children who receive regular blood transfusions are then at risk for iron overload. Chelation, or iron-reduction, therapy is needed for those receiving transfusions. The National Institutes of Health (NIH)-supported study sought to answer whether hydroxyurea would provide the same benefit as blood transfusions, given these additional treatment impacts. Hydroxyurea is the only drug approved by the Food and Drug Administration to treat sickle cell disease. The Transcranial Doppler with Transfusions Changing to Hydroxyurea (TWiTCH) study was stopped early due to positive preliminary results in November 2014.
Researchers from 26 clinical sites supported by the NIH's National Heart, Lung, and Blood Institute (NHLBI) recruited and studied 121 children ages 4 to 16 years old and divided them into two groups: one that received transfusions and one that was transitioned from transfusions to daily doses of hydroxyurea.
"No child should ever have to face the prospect of suffering through a stroke," said Gary H. Gibbons, M.D., director of the NHLBI. "Our institute is striving to achieve a stroke-free generation of children living with sickle cell disease. Studies like this are vital for moving us toward this worthwhile goal."
Study authors indicated that the findings suggest that hydroxyurea could be effective at reducing risk of stroke for other patient populations, though this was not a primary goal of the study.

Story Source:
The above post is reprinted from materials provided by Medical University of South Carolina. Note: Materials may be edited for content and length.

How Vitamin A can Reduce Scarring in Blood Vessels

2016-01-29T08:23:00.000+05:30

While scarring is a natural part of any healing process, scar formation within our blood vessels can be deadly. A team of US researchers has developed a new biodegradable material with built-in vitamin A which has been shown to reduce scarring in blood vessels.

"When injury occurs, cells proliferate and migrate into the blood vessel, creating scar-like tissue. It can create blockages that impair blood flow," said lead researcher Guillermo Ameer from the Northwestern University.

The soft elastic material can be used to treat injured vessels or be used to make medical devices such as stents and prosthetic vascular grafts. Early tests have shown that the material can reduce cell migration - a major contributor to the scarring process - by 57%.

"In his new work, vitamin A is integrated into the material, harnessing the beneficial properties of vitamin A and allowing for its broader application in medical devices," the authors noted in a paper published in the ACS Biomaterials Science and Engineering.

This new advanced material brings together two major advantages. Its antioxidant component can reduce the oxidative stress that leads to chronic inflammation.

Vitamin A, which is released as the material degrades, can prevent or reduce scarring.

It can potentially also be used outside the body such as for wound-healing bandages for diabetic patients.

Because the new material releases vitamin A as it degrades, the potential for toxic build up is much lower.

Ameer's team can also control how quickly the material degrades - and thus releases the vitamin A - depending on how the material is produced in the laboratory.

The team now plans to explore the material's potential for additional applications. Vitamin A is already widely known for its anti-aging properties and topical antioxidants can be used to combat cell damage or improve wound healing.

Source: IANS

Encapsulated Human Islet Cells can Normalize Blood Sugar Read more: Encapsulated Human Islet Cells can Normalize Blood Sugar

2016-01-29T08:20:00.002+05:30

Scientists studying a mouse model of diabetes have implanted encapsulated insulin-producing cells derived from human stem cells and maintained long-term control of blood sugar -- without administering immunosuppressant drugs.

The results of the multi-institutional effort are published in Nature Medicine. People with type 1 diabetes have an overactive immune system that destroys the insulin-producing islet cells in the pancreas. Lacking that hormone, the body fails to convert sugars to usable energy, and glucose rises to harmful levels in the blood without daily insulin injections.

Islet cells have been successfully transplanted to treat type 1 diabetes, but those patients must take immunosuppressant drugs to keep their immune system from destroying the transplanted cells. Previous research had shown that rodent islet cells could normalize blood sugar levels in animal models without immunosuppression if the cells were encased in hydrogel capsules.

The semi-porous capsules allow insulin to escape into the blood, while preventing the host's immune system from attacking the foreign cells. Larger capsules, about 1.5 millimeters across, even seemed able to avoid the buildup of scar tissue, which can choke off the cells' supply of oxygen and nutrients. The new study, a collaboration led by scientists at the Massachusetts Institute of Technology and Boston Children's Hospital, used islet cells derived from human stem cells and capsules made of chemically-tweaked gel that are even more resistant to the build-up of scar tissue.

Dr. Jose Oberholzer, chief of transplantation surgery and director of cell and pancreas transplantation at the University of Illinois Hospital & Health Sciences System, professor of bioengineering at the University of Illinois at Chicago, and an author on the paper, tested several varieties of chemically-modified alginate hydrogel spheres -- in various sizes -- to see if any excelled at resisting scar-tissue formation.

Oberholzer and his coworkersat the University of Illinois at Chicago first tested the spheres to ensure they would allow the islet cells to function inside a host. Using a special microfluidic device developed at UIC under a grant from the National Institute of Diabetes and Digestive and Kidney Diseases, they delivered minute amounts of glucose into tiny wells containing encapsulated islet cells and measured the amount of insulin that seeped out.

They implanted spheres that showed promise into rodents and non-human primates to look for the development of scar tissue. They found (and reported in the journal Nature Biotechnology) that 1.5-millimeter spheres of triazole-thiomorphine dioxide (TMTD) alginate were best at allowing allowing insulin to escape while resisting immune response and the buildup of scar tissue. When implanted into a mouse model of diabetes, TMTD-alginate spheres containing human islet cells were able to maintain proper blood glucose control for 174 days -- decades, in terms relative to the human lifespan.

"When we stopped the experiment and took the spheres out, they were virtually free of scar tissue," Oberholzer said. "While this is a very promising step towards an eventual cure for diabetes, a lot more testing is needed to ensure that the islet cells don't de-differentiate back toward their stem-cell states or become cancerous," said Oberholzer. If the cells did become cancerous, he said, they could easily break through the spheres.

Oberholzer also cautioned that a cure for human diabetes would require scientists to develop techniques to grow large numbers of human islet cells from stem cells -- a worthy goal. "In the United States, there are 30 million cases of type 2 diabetes and about 2 million patients with type 1 diabetes who could potentially benefit from such a procedure," he said. "But we need to grow billions of islet cells."

Source: Eurekalert

Three Simple Suggestions for a Healthy Diet

2016-01-28T16:20:00.001+05:30

In the article below, Ellen Fung, PhD, RD of UCSF Benioff Children’s Hospital Oakland and Farah Sultan, RD of McMaster University, share some nutritional information for people with thalassemia.

One of the most common questions we are asked as nutritionists is, “What should I be eating?” In many ways, the diet for individuals with thalassemia is no different than for anyone else: the key is balance. However, the needs for certain nutrients are much higher in thalassemia. Therefore, nutrient density is very important! This means every calorie must count. Rather than worrying about which specific foods are “good” for you or which foods are “bad,” it’s better to focus on choosing a variety of foods that are packed with vitamins, minerals, fiber and other nutrients. Making smart, balanced food choices every day can help you stay healthy.
Here are some strategies you can use:

Eating Around the Rainbow: Healthy foods we eat come in a variety of colors: kale (green), carrots (orange), beets (red), red cabbage (purple). Fruit loops don’t count here! Each food derives its color from the rich concentration of antioxidants in its skin and flesh. The variety of colors comes from a diverse range of anthocyanins (plant pigments) and antioxidants (for example, carrots and sweet potatoes are orange because of the antioxidant, beta-carotene). By eating a variety of foods of different colors throughout the day (eating around the rainbow), you will be consuming more antioxidants, substances which are important for reducing the damage that can be caused by the free iron in your body.

My Plate: Smaller Portions, More Vegetables and Fruit. If you are not familiar with the “My Plate” campaign from the USDA, you should take a look at it (see below and at www.choosemyplate.gov). This newest guideline for eating healthy is a simple set-up of a small plate which is divided into portions, roughly ¼ for protein, ¼ for grain/carbohydrates and ½ of the plate set aside for fruits & vegetables. If we ate all our meals this way, we would be consuming many more vitamins and minerals in our diet. Think about this the next time you sit down for lunch and dinner.

Eat Food, not Supplements. The best way to get all of our nutrients is through our food. Most nutrients are best absorbed when they come from our food (e.g. calcium – milk, zinc – chicken) rather than in the form of supplements. Nutrients found within foods are created in such a way to avoid competition for absorption in your body whereas the form of nutrients in some supplements may result in poor absorption. Food also contains much needed fiber as well as other substances (phytochemicals, flavonoids) that are important for your health. When healthy foods are replaced by foods with poor nutrient density (e.g. empty calories) + dietary supplements, you miss out on all of the benefits of food. Not to mention the simple joys of consuming delicious, nutritious foods! However, we must be clear…Individuals with thalassemia may require certain supplements (e.g. vitamin D) in addition to their diet; but supplementation should NOT REPLACE a healthy diet.

Making healthy choices doesn’t have to be complicated — simply begin by making one change in your daily routine, such as making sure to have one colorful vegetable every day. You may just be surprised how simple it can be, and how great you can feel.
Ellen Fung, PhD RD
Associate Research Scientist
UCSF Benioff Children’s Hospital Oakland
Oakland, CA USA
Farah Sultan, RD
Master’s Degree Student, Nutritional Science
McMaster University
Toronto, ON Canada

Educating Public on Sickle Cell Disease Risk

2014-11-28T16:38:00.002+05:30

In sub-Saharan Africa, members of the public who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring with the disease if their partner is also a carrier.

This is according to research published in the International Journal of Medical Engineering and Informatics. There are many physical and emotional public health components of sickle cell disease, explains William Ebomoyi of the Department of Health Studies College of Health Sciences, Chicago State University, Illinois, USA. Moreover, there ethical and legal considerations surrounding the screening of newborns for this potentially lethal disease.

Sickle-cell disease (SCD), also known as sickle-cell anemia (SCA) or drepanocytosis is an inherited condition in which a child of parents both of whom are carriers of the associated hemoglobin gene who inherits both copies will produce abnormal red blood cells that are rigid and often sickle-shaped. The disorder causes both acute and chronic health problems, such as repeated infections, severe attacks of pain and potentially stroke and death. Carriers of just one copy of this particular hemoglobin gene tend to have greater resistance to the lethal parasitic disease malaria compared to people without a copy of the gene. However, around 2 percent of the population of sub-Saharan Africa is born with SCD. Moreover, incidence is rising across the globe as populations migrate.

In the age of genomics, however, Ebomoyi suggests that raising awareness of the risks of having children with SCD if both parents are carriers is important. "An aggressive health education of the public is required to maintain a shared responsibility for their courtship behaviour by alerting potential suitors of their heterozygous status," he suggests. He adds that, "Major sickle cell education programmes need to be integrated into the curriculum of elementary, secondary and tertiary academic institutions."

Successful outcome prompts early end to sickle cell anemia clinical trial

2014-11-28T16:35:00.000+05:30

Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute (NHLBI) of a key clinical trial studying the drug's efficacy.

NHLBI officials issued the announcement today, about one year before the study was originally scheduled to end. Going by the title TWiTCH (TCD With Transfusions Changing to Hydroxyurea), the Phase III randomized clinical trial at 25 medical centers in the U.S. and Canada compared standard therapy (monthly erythrocyte transfusions) with the alternative (daily hydroxyurea) for children with elevated transcranial Doppler (TCD) velocities and high risk of stroke.

"Early results indicate that TWiTCH is a success. Hydroxyurea works as well as blood transfusions to lower TCD velocities, which lowers the risk of the child having a stroke," said Russell E. Ware, MD, PhD, principal investigator of the study and director of Hematology at Cincinnati Children's Hospital Medical Center, which served as the study's Medical Coordinating Center.

"A group of outside experts has been reviewing the TWiTCH data every few months to ensure the safety of children in the clinical trial and to monitor the data," Ware explained. "This group met recently and after careful consideration of the interim data results, recommended that the study be stopped since hydroxyurea worked as well as transfusions to lower TCD velocities." The NHLBI and National Institutes of Health (NIH) agreed with the recommendation.

"No child should ever suffer a stroke, which is why it was so important for the NHLBI to support the TWiTCH trial," said Gary Gibbons, MD, director of the NHLBI. "This critical research finding opens the door to more treatment options for clinicians trying to prevent strokes in children living with the sickle cell disease."

The study enrolled its first patient in September 2011 and included children between ages 4 and 16 years with sickle cell anemia and abnormally elevated TCD velocities, which increases their risk of developing a stroke. The current standard therapy for children with elevated TCD velocities is monthly blood transfusions. A total of 121 children were randomized: half received the standard therapy of transfusions while the other half received the alternate treatment with daily hydroxyurea, which has not yet been approved for children with sickle cell anemia.

The clinical data-collection portion of the study was originally scheduled for 24 months, but collection is now being stopped early, after only half of the children have completed the treatment phase.

"We did not know if hydroxyurea would reduce the risk of stroke as well as transfusions, so TWiTCH was an important research study," said Barry R. Davis, MD, PhD, principal investigator for the Data Coordinating Center at the University of Texas Health Science Center at Houston (UTHealth) School of Public Health. "The study has now shown that hydroxyurea has a similar benefit as transfusions, so the study is closing early since the main research question has been answered."

An important reason for testing hydroxyurea is that the current standard therapy of monthly blood transfusions to reduce stroke risk can lead to problems such as antibody formation and iron overload, which are increasingly recognized as a source of morbidity in young patients with SCA.
Over the past decade, the laboratory and clinical efficacy of hydroxyurea has been demonstrated in children and adults with SCA. Originally developed as a drug to treat cancer and infections, hydroxyurea boosts fetal hemoglobin production in SCA, which prevents the red blood cells from acquiring the sickled shape that fuels the many complications. Hydroxyurea has been previously shown to have clinical efficacy for a variety of sickle-related complications, but TWiTCH is the first Phase III trial that demonstrates its benefits for children with cerebrovascular disease and increased stroke risk.